{
  "$schema": "folio-library-document/v1",
  "id": "10665-349550",
  "title": "Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus",
  "variant": "pdf",
  "pages": 86,
  "tocSource": "undetermined",
  "tocMethod": "contents",
  "toc": [],
  "sections": [
    {
      "id": "page-001",
      "number": null,
      "title": "Page 1",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 1,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 24,
      "summary": {
        "text": "The cover page of the 2021 WHO global guidance on criteria and processes for validating elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "GUIDANCE MONITORING AND EVALUATION GLOBAL GUIDANCE ON CRITERIA AND PROCESSES FOR VALIDATION: ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION OF HIV, SYPHILIS AND HEPATITIS B VIRUS 2021",
      "extractCut": false,
      "blocks": [
        "library/10665-349550/blocks/prose-page-001"
      ]
    },
    {
      "id": "page-002",
      "number": null,
      "title": "Page 2",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 5,
      "summary": {
        "text": "A blank page with no text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-349550/blocks/prose-page-002"
      ]
    },
    {
      "id": "page-003",
      "number": null,
      "title": "Page 3",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 3,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 20,
      "summary": {
        "text": "The inner title page of the 2021 global guidance on validating elimination of mother-to-child transmission of HIV, syphilis and hepatitis B.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "GLOBAL GUIDANCE ON CRITERIA AND PROCESSES FOR VALIDATION: ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION OF HIV, SYPHILIS AND HEPATITIS B VIRUS 2021",
      "extractCut": false,
      "blocks": [
        "library/10665-349550/blocks/prose-page-003"
      ]
    },
    {
      "id": "page-004",
      "number": null,
      "title": "Page 4",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 545,
      "summary": {
        "text": "The copyright and cataloguing page of the 2021 EMTCT validation guidance, noting it updates the 2017 edition and giving ISBNs, licence terms and disclaimers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "global guidance",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus This publication is the update of the document published in 2017 entitled “Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis, second edition”. ISBN 978-92-4-003936-0 (electronic version) ISBN",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-004"
      ]
    },
    {
      "id": "page-005",
      "number": null,
      "title": "Page 5",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "iii",
      "labelEnd": "iii",
      "words": 340,
      "summary": {
        "text": "The table of contents of the EMTCT validation guidance, listing chapters on rationale, indicators and targets, validation processes and annexes on measuring HBV indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation process",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "standardized criteria",
          "heading": false
        },
        {
          "term": "special populations",
          "heading": false
        },
        {
          "term": "children exposed",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        }
      ],
      "extract": "CONTENTS FOREWORD iv ACKNOWLEDGEMENTS vi ESSENTIAL WHO EMTCT RESOURCES viii ABBREVIATIONS AND ACRONYMS ix GLOSSARY x EXECUTIVE SUMMARY xiii 1. INTRODUCTION 1 1.1. \u0007MOTHER-TO-CHILD TRANSMISSION IN THE 1 HIV, SYPHILIS AND HBV EPIDEMICS 1.2. \u0007TRIPLE ELIMINATION OF MOTHER-TO-CHILD 3 TRANSMISSION AND ITS VALIDATION 1.3. STANDARD CRITERIA AND PROCESSES 4 2. \u0007RATIONALE FOR STANDARDIZED CRITERIA 7 AND PROCESSES FOR EMTCT OF",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-005"
      ]
    },
    {
      "id": "page-006",
      "number": null,
      "title": "Page 6",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "iv",
      "labelEnd": "iv",
      "words": 496,
      "summary": {
        "text": "A foreword recounting the history of global efforts to validate elimination of mother-to-child transmission of HIV and syphilis since 2014, including Cuba's validation in 2015. It stresses human rights and the involvement of women living with HIV or HBV in services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "child health",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        }
      ],
      "extract": "The global community has committed to eliminating mother-to-child transmission (EMTCT), also known as vertical transmission, of HIV and syphilis as a public health priority. In 2014 the World Health Organization (WHO) released the first edition of the Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis. In 2015 the Global Validation Advisory",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-006"
      ]
    },
    {
      "id": "page-007",
      "number": null,
      "title": "Page 7",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "v",
      "labelEnd": "v",
      "words": 157,
      "summary": {
        "text": "Continuation of the foreword, explaining that this third version sets standard criteria for validating triple elimination and recognising high-burden countries on the Path to Elimination, signed by the WHO HIV, hepatitis and STI programmes director.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "elimination",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "triple",
          "heading": false
        },
        {
          "term": "multilevel",
          "heading": false
        }
      ],
      "extract": "Foreword This third version of the EMTCT global validation guidance document provides standardized processes and consensus-developed criteria to validate EMTCT of HIV, syphilis and HBV and to recognize high burden countries that have made significant progress on the Path to Elimination. The guidance strongly emphasizes country-led accountability, rigorous analysis, intensive programme assessment and multilevel",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-007"
      ]
    },
    {
      "id": "page-008",
      "number": null,
      "title": "Page 8",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": "vi",
      "labelEnd": "vi",
      "words": 446,
      "summary": {
        "text": "Acknowledges the WHO programmes, Global Validation Advisory Committee members and others who developed the guidance, describing how the third version was produced through virtual meetings and consultation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation advisory",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "advisory committee",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "observers",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        }
      ],
      "extract": "ACKNOWLEDGEMENTS This guidance document is the result of collaboration between the WHO Global HIV, Hepatitis and STI Programmes, led by their Director, Meg Doherty, the Global Validation Advisory Committee for elimination of mother-to-child transmission (GVAC) members and observers, WHO counterpart programmes at the regional and country levels, and contributing member states. Many professionals from a range of",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-008"
      ]
    },
    {
      "id": "page-009",
      "number": null,
      "title": "Page 9",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "vii",
      "labelEnd": "vii",
      "words": 185,
      "summary": {
        "text": "Continues the acknowledgements, naming regional EMTCT focal points and WHO staff and noting PEPFAR funding through CDC and USAID.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "guidance revision",
          "heading": false
        },
        {
          "term": "region",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "contributed",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "past",
          "heading": false
        },
        {
          "term": "health",
          "heading": false
        }
      ],
      "extract": "Acknowledgements Past and current advisors and EMTCT focal points from the six WHO regions contributed to the guidance revision based on the experiences from national and regional EMTCT validation committees, secretariats and teams. African Region: Francoise Bigirimana, Innocent Nuwagira. Region of the Americas: Sandra Jones, Leandro Sereno, Massimo Ghidinelli. South-East Asia Region: Mukta Sharma, B.B. Rewari.",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-009"
      ]
    },
    {
      "id": "page-010",
      "number": null,
      "title": "Page 10",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 10,
      "labelStart": "viii",
      "labelEnd": "viii",
      "words": 106,
      "summary": {
        "text": "Lists essential WHO web resources on triple elimination, validation processes, regional websites and related guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "syphilis-and-hepatitis-b validation",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "regional office",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        }
      ],
      "extract": "Additional information on EMTCT of HIV, syphilis and HBV, including updated tools and other guidance, are available on the WHO websites: Triple elimination initiative of EMTCT of HIV, syphilis and HBV https://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv- syphilis-and-hepatitis-b/validation EMTCT validation processes and tools",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-010"
      ]
    },
    {
      "id": "page-011",
      "number": null,
      "title": "Page 11",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "ix",
      "labelEnd": "ix",
      "words": 245,
      "summary": {
        "text": "A list of abbreviations and acronyms used in the guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "national validation",
          "heading": false
        },
        {
          "term": "hepatitis",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        }
      ],
      "extract": "ABOs adverse birth outcomes ANC antenatal care ART antiretroviral therapy ARV antiretroviral CDC \u0007United States Centers for Disease Control and Prevention CHB chronic hepatitis B CS congenital syphilis CSF cerebrospinal fluid EID early infant diagnosis EMTCT \u0007elimination of mother-to-child transmission EQA external quality assurance FPC finite population correction GAM UNAIDS Global AIDS Monitoring GHSS global",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-011"
      ]
    },
    {
      "id": "page-012",
      "number": null,
      "title": "Page 12",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "x",
      "labelEnd": "x",
      "words": 485,
      "summary": {
        "text": "Glossary entries taken from WHO guidelines, defining terms such as adequate syphilis treatment, early infant diagnosis and informed consent.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "informed consent",
          "heading": false
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "infant diagnosis",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "hbeag",
          "heading": false
        },
        {
          "term": "health problem",
          "heading": false
        }
      ],
      "extract": "The following glossary definitions are sourced from current relevant WHO guidelines (1-5). Adequate treatment of syphilis: The treatment of seropositive women with at least one dose of intramuscular benzathine penicillin G at least 30 days prior to delivery is the minimum time necessary to prevent transmission of syphilis to the infant. Ideally, maternal treatment should be given in the first trimester, or as early",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-012"
      ]
    },
    {
      "id": "page-013",
      "number": null,
      "title": "Page 13",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "xi",
      "labelEnd": "xi",
      "words": 525,
      "summary": {
        "text": "Further glossary definitions, covering terms such as integrated service delivery, integration, quality assurance and quality control.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "care services",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "quality requirements",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "non-treponemal",
          "heading": false
        }
      ],
      "extract": "Glossary Integrated service delivery: Health services that are managed and delivered in a way that ensures that people receive a continuum of health promotion, infection prevention, diagnosis, treatment, disease management, rehabilitation and palliative care services at the different levels and sites of care within the health system and according to their needs throughout the life-course. Integration: The",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-013"
      ]
    },
    {
      "id": "page-014",
      "number": null,
      "title": "Page 14",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "xii",
      "labelEnd": "xii",
      "words": 224,
      "summary": {
        "text": "The final glossary entries, defining terms such as quality management system, rapid diagnostic test, testing algorithm and validation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "treponema pallidum",
          "heading": false
        },
        {
          "term": "testing algorithm",
          "heading": false
        },
        {
          "term": "treponemal",
          "heading": false
        },
        {
          "term": "testing strategy",
          "heading": false
        },
        {
          "term": "antibodies",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "sampling",
          "heading": false
        },
        {
          "term": "product",
          "heading": false
        }
      ],
      "extract": "Quality management system: A system to direct and control an organization with regard to quality. Systematic and process-oriented efforts are essential to meet quality objectives. Rapid diagnostic test (RDT): Immunoassays that detect antibodies or antigens and can give a result in less than 30 minutes. Most RDTs can be performed with capillary whole blood collected by finger-stick sampling and some, by oral fluid",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-014"
      ]
    },
    {
      "id": "page-015",
      "number": null,
      "title": "Page 15",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "xiii",
      "labelEnd": "xiii",
      "words": 578,
      "summary": {
        "text": "Opens the executive summary by describing the global commitment to eliminate vertical transmission of HIV, syphilis and HBV and the purpose of the goal. It cites 2030 targets including zero new infant HIV infections and HBsAg prevalence of 0.1% or less in young children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "triple elimination",
          "heading": false
        },
        {
          "term": "mch services",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "hiv infections",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        }
      ],
      "extract": "The global community has committed to the elimination of mother-to-child transmission (MTCT), also referred to as vertical transmission, of HIV, syphilis and hepatitis B virus (HBV) as a public health priority. The global commitment to EMTCT was established due to the continued high global burden of mother-to-child (MTCT), or vertical transmission, of these infections. The purpose of the elimination goal is to",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-015"
      ]
    },
    {
      "id": "page-016",
      "number": null,
      "title": "Page 16",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "xiv",
      "labelEnd": "xiv",
      "words": 331,
      "summary": {
        "text": "Recounts the development of the EMTCT validation guidance from the 2014 \"Orange Book\" through later editions, with requirements in data, laboratory, programme and human rights areas. It introduces a summary table of targets.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "global guidance",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        },
        {
          "term": "elimination",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "criteria",
          "heading": false
        },
        {
          "term": "targets",
          "heading": false
        }
      ],
      "extract": "In 2014 WHO led a global consultation that resulted in the first edition of Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis, also known as the “Orange Book”. This guidance document supported the standardization and formal approach to EMTCT validation, including criteria, indicators and targets to be achieved. These formed the basis for",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-016"
      ]
    },
    {
      "id": "page-017",
      "number": null,
      "title": "Page 17",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "xv",
      "labelEnd": "xv",
      "words": 409,
      "summary": {
        "text": "A table summarising impact and programme targets for eliminating mother-to-child transmission of HIV, syphilis and HBV, from 2030 global targets to specific validation thresholds, with explanatory footnotes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "live births",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "case rate",
          "heading": false
        },
        {
          "term": "targets",
          "heading": false
        }
      ],
      "extract": "Executive summary Table 1. \u0007Summary of impact and process/programmatic targets for EMTCT of HIV, syphilis and HBV Elimination targets HIV EMTCT Syphilis EMTCT HBV EMTCT 2030 WHO GHSS (8, 10, 11) and UNGA political declaration (13) aspirational targets Zero new infections among infants and young children and achievement of the 95-95-95 targets ≤50 cases of CS per 100 000 live births in 80% of countries 95% reduction",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-017",
        "library/10665-349550/blocks/table-001"
      ]
    },
    {
      "id": "page-018",
      "number": null,
      "title": "Page 18",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "xvi",
      "labelEnd": "xvi",
      "words": 539,
      "summary": {
        "text": "Lists the changes in the third version of the guidance, such as adding HBV validation criteria and Path to Elimination recognition, revising laboratory quality standards and expanding guidance on low-performing subnational units. It ends by expressing WHO's hope that the guidance will speed progress.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation processes",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "validation advisory",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "gmef",
          "heading": false
        },
        {
          "term": "advisory committee",
          "heading": false
        }
      ],
      "extract": "Changes, clarifications and new guidance in this third version address the following topics areas: 1. \u0007inclusion of validation criteria and processes for EMTCT of HBV (section 3.1.3), including criteria for the recognition of progress in countries with a high burden of HBV (PTE) (section 5); 2. \u0007revision of laboratory quality standards, including external quality assurance (EQA) for validation (section 4.2); 3.",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-018"
      ]
    },
    {
      "id": "page-019",
      "number": null,
      "title": "Page 19",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 443,
      "summary": {
        "text": "Describes the contribution of vertical transmission to the HIV epidemic, with UNAIDS estimates of new child infections in 2020 compared with the 2000 peak. It notes that the guidance also applies to trans and gender diverse people who can become pregnant.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "acquiring hiv",
          "heading": false
        },
        {
          "term": "hiv through",
          "heading": false
        },
        {
          "term": "through breastfeeding",
          "heading": false
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "become pregnant",
          "heading": false
        }
      ],
      "extract": "1.1. \u0007Mother-to-child transmission in the HIV, syphilis and HBV epidemics Mother-to-child transmission (MTCT), or “vertical transmission”, is a significant contributor to the HIV pandemic, accounting for 9% of new infections globally in 2017 (15). The Joint United Nations Programme on HIV/AIDS (UNAIDS) reported that, globally, in 2020 an estimated 150 000 children newly acquired HIV, and an estimated 1.8 million",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-019"
      ]
    },
    {
      "id": "page-020",
      "number": null,
      "title": "Page 20",
      "level": 1,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 613,
      "summary": {
        "text": "Lists key interventions for preventing vertical HIV transmission, then describes the burden of congenital syphilis and of HBV, noting that most chronic HBV infections are acquired in childhood.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "abos",
          "heading": false
        },
        {
          "term": "liver cancer",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "anc",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "hepatitis",
          "heading": false
        }
      ],
      "extract": "2 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus • universal and equitable access to HTS for pregnant and breastfeeding women; • initiation of lifelong triple antiretroviral therapy (ART) for pregnant women living with HIV, with support for adherence; • retention in care and viral suppression for pregnant and postpartum women and girls living with HIV; • safe delivery practices;",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-020"
      ]
    },
    {
      "id": "page-021",
      "number": null,
      "title": "Page 21",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 600,
      "summary": {
        "text": "Notes WHO's recommendation for hepatitis B birth dose and infant vaccination, then explains how elimination of vertical transmission is defined and validated as a public health problem. It also describes regional frameworks for triple elimination, such as in the Western Pacific.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "triple elimination",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "mch",
          "heading": false
        },
        {
          "term": "requires strong",
          "heading": false
        },
        {
          "term": "public health",
          "heading": false
        }
      ],
      "extract": "1. Introduction this leads to chronic disease much less often. WHO recommends universal immunization of infants with at least three doses of the hepatitis B vaccine and timely hepatitis B birth dose (HepB-BD) vaccination (as soon as possible after birth, preferably within 24 hours) (27). 1.2. \u0007Triple elimination of mother-to-child transmission and its validation In public health elimination is generally defined as",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-021"
      ]
    },
    {
      "id": "page-022",
      "number": null,
      "title": "Page 22",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 593,
      "summary": {
        "text": "Defines validation as confirmation that a country has met EMTCT criteria while protecting human rights and involving women living with HIV or HBV. It outlines the history of earlier editions of the guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation advisory",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "validation structures",
          "heading": false
        },
        {
          "term": "country validation",
          "heading": false
        },
        {
          "term": "hepatitis elimination",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "interim guidance",
          "heading": false
        }
      ],
      "extract": "4 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus “Validation” is a term used to attest that a country has successfully met the criteria for EMTCT of HIV and/or syphilis and/or HBV. A unique consideration for validation of EMTCT is that elimination must be achieved while protecting and respecting human rights. It must also include the meaningful involvement of women, particularly",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-022"
      ]
    },
    {
      "id": "page-023",
      "number": null,
      "title": "Page 23",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 395,
      "summary": {
        "text": "A box summarising what is new in the third version, including HBV criteria, laboratory standards and subnational selection, and describing the Path to Elimination category for high-burden countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "syphilis-positive pregnant",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "time intervals",
          "heading": false
        },
        {
          "term": "section",
          "heading": false
        },
        {
          "term": "revision",
          "heading": false
        },
        {
          "term": "pte",
          "heading": false
        }
      ],
      "extract": "Box 1.2. What’s new in the third version This third version includes changes, clarifications and new guidance on criteria and processes for validation, including the following: 1. inclusion of validation criteria and processes for EMTCT of HBV (section 3.1.3), including criteria for the recognition of progress in countries with a high burden of HBV (PTE) (section 5); 2. revision of laboratory quality standards,",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-023"
      ]
    },
    {
      "id": "page-024",
      "number": null,
      "title": "Page 24",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 559,
      "summary": {
        "text": "Recaps revisions made in the second edition and explains that the third version adds HBV for triple elimination, noting Botswana as the first country recognised on the Path to Elimination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "meaningful engagement",
          "heading": false
        },
        {
          "term": "syphilis-positive pregnant",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "community engagement",
          "heading": false
        }
      ],
      "extract": "6 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Also revised in the second edition were the (i) criteria for evaluation of human rights, gender equality and community engagement, (ii) surveillance case definition of CS, which was expanded, (iii) maintenance of validation requirements and (iv) guidance on special circumstances and special populations. This third version now moves",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-024"
      ]
    },
    {
      "id": "page-025",
      "number": null,
      "title": "Page 25",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 440,
      "summary": {
        "text": "Sets out the qualifying requirements countries should meet before applying for validation, including national-level evidence of meeting targets, and recommends a preliminary self-assessment checklist.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "emtct validation",
          "heading": false
        },
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "validation process",
          "heading": false
        },
        {
          "term": "lowest performing",
          "heading": false
        },
        {
          "term": "subnational administrative",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "administrative units",
          "heading": false
        },
        {
          "term": "indicator targets",
          "heading": false
        }
      ],
      "extract": "2.1. \u0007Qualifying requirements for EMTCT of HIV, syphilis and HBV Before initiating the validation process, countries should be confident that they can meet the global minimum criteria listed below. They are advised to complete the Checklist for country preliminary assessment of EMTCT and Path to Elimination criteria (34) (Web Annex A), which is currently being updated to include EMTCT of HBV. Any country that feels",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-025"
      ]
    },
    {
      "id": "page-026",
      "number": null,
      "title": "Page 26",
      "level": 1,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 447,
      "summary": {
        "text": "Continues the qualifying requirements, covering surveillance systems able to detect most vertical infections, meeting criteria in the lowest-performing subnational unit, and programme, human rights and community engagement requirements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "standardized criteria",
          "heading": false
        },
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "mch",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": false
        }
      ],
      "extract": "8 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus [3] Existence of an adequate national monitoring and surveillance system that can capture process data from the whole health sector, comprising both the public and non-public health sectors, and can detect a majority of the cases of MTCT of HIV, syphilis and HBV. Data from this system can be used for modelling infant HIV, syphilis",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-026"
      ]
    },
    {
      "id": "page-027",
      "number": null,
      "title": "Page 27",
      "level": 1,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 408,
      "summary": {
        "text": "Explains the epidemiological and programme considerations behind the validation criteria, such as frequent asymptomatic infection, the importance of testing and treatment in pregnancy, infant HBV vaccination and protection of women's rights.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infant hbv",
          "heading": false
        },
        {
          "term": "hbv infection",
          "heading": false
        },
        {
          "term": "benzathine penicillin",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        }
      ],
      "extract": "2. Rationale for standardized criteria and processes for EMTCT of HIV, syphilis and HBV The criteria selected for measuring EMTCT of HIV, syphilis and HBV take into account the following aspects of HIV, syphilis and HBV epidemiology and available prevention interventions, treatment and care: • HIV, syphilis and HBV infection can very often be asymptomatic in adults and infants or young children, meaning that",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-027"
      ]
    },
    {
      "id": "page-028",
      "number": null,
      "title": "Page 28",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 242,
      "summary": {
        "text": "A table of country options for single, dual or triple validation, with a note that countries should report data on all three infections even if seeking single or dual validation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "triple validation",
          "heading": false
        },
        {
          "term": "dual validation",
          "heading": false
        },
        {
          "term": "single validation",
          "heading": false
        },
        {
          "term": "triple elimination",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "indicators",
          "heading": false
        }
      ],
      "extract": "Table 3.1. \u0007Country options for applications for single, dual or triple validation of EMTCT of HIV, syphilis and HBV *\u0007Single validation for HBV is done at the regional level (3). Upon special request from the regional validation secretariat or committee, single validation for HBV may be reviewed at the global level and will include reporting on HIV and syphilis. Validation indicators and targets are used to monitor",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-028",
        "library/10665-349550/blocks/table-002"
      ]
    },
    {
      "id": "page-029",
      "number": null,
      "title": "Page 29",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 389,
      "summary": {
        "text": "A box summarising the impact and process targets required for global validation of EMTCT of HIV, syphilis and HBV, such as MTCT rates, case rates and HBsAg prevalence thresholds.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "serosurveys",
          "heading": false
        },
        {
          "term": "hbsag-positive",
          "heading": false
        }
      ],
      "extract": "Box 3.1. \u0007Summary of required impact and process targets for global validation of EMTCT of HIV, syphilis and HBV EMTCT IMPACT TARGETS (Must be the most recent verified data and must be achieved for at least one year) • MTCT rate of HIV of <2% in non-breastfeeding populations OR <5% in breastfeeding populations (see section 6.2) • a population case rate of new paediatric HIV infections due to MTCT of ≤50 cases per",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-029"
      ]
    },
    {
      "id": "page-030",
      "number": null,
      "title": "Page 30",
      "level": 1,
      "pageStart": 30,
      "pageEnd": 30,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 212,
      "summary": {
        "text": "Sets out the two impact targets for validating EMTCT of HIV, an MTCT rate below 5% or 2% and 50 or fewer paediatric cases per 100 000 live births, and describes recommended infant testing schedules.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "live births",
          "heading": false
        },
        {
          "term": "case rate",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "impact indicators",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        }
      ],
      "extract": "12 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus 3.1. \u0007Impact indicators and targets for validation of EMTCT 3.1.1 Impact indicators and targets for validation of EMTCT of HIV Prior to submission of the application for validation, countries are required to have achieved and maintained for at least one year both of the following impact targets for validating EMTCT of HIV: • an",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-030"
      ]
    },
    {
      "id": "page-031",
      "number": null,
      "title": "Page 31",
      "level": 1,
      "pageStart": 31,
      "pageEnd": 31,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 353,
      "summary": {
        "text": "Explains the HIV MTCT rate and how it relates to the case rate, giving a formula for calculating the case rate from maternal prevalence and MTCT rate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "live births",
          "heading": false
        },
        {
          "term": "vertical infections",
          "heading": false
        },
        {
          "term": "vertical hiv",
          "heading": false
        },
        {
          "term": "target mtct",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "case rate",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        }
      ],
      "extract": "The MTCT rate measures vertical transmission (that is, the percentage of vertical infections among births to women living with HIV) and specifically measures the impact of treatment programmes for preventing vertical infections. The MTCT rate is closely related to the case rate but does not capture all of the interventions required to reach EMTCT (Box 3.3). With effective interventions and a high level of maternal",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-031"
      ]
    },
    {
      "id": "page-032",
      "number": null,
      "title": "Page 32",
      "level": 1,
      "pageStart": 32,
      "pageEnd": 32,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 533,
      "summary": {
        "text": "A box on the rationale for using a case rate of new paediatric HIV infections, listing its advantages for comparability and for reflecting prevention efforts. It notes that process indicators should cover all pregnant women living with HIV, including migrants and key populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "case rate",
          "heading": false
        },
        {
          "term": "among women",
          "heading": false
        },
        {
          "term": "hiv infections",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "child infections",
          "heading": false
        }
      ],
      "extract": "14 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Box 3.3. \u0007Rationale for use of a case rate of new paediatric HIV infections due to vertical transmission The use of a case rate as a standard metric has three advantages: 1. Presenting the case rate as per 100 000 births allows for a measure that is comparable across different country population sizes. 2. It considers maternal",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-032"
      ]
    },
    {
      "id": "page-033",
      "number": null,
      "title": "Page 33",
      "level": 1,
      "pageStart": 33,
      "pageEnd": 33,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 484,
      "summary": {
        "text": "Lists limitations of HIV vertical transmission and case rates drawn from studies and household surveys, such as missing women outside PMTCT programmes, maternal seroconversion during pregnancy or breastfeeding, early child deaths and loss to follow-up. It recommends modelled estimates as a remedy, noting their weaker reliability in low-prevalence concentrated epidemics, and begins explaining how the Spectrum model accounts for breastfeeding duration and maternal treatment timing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "spectrum estimates",
          "heading": false
        },
        {
          "term": "modelled estimates",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "breastfeeding duration",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "miss",
          "heading": false
        },
        {
          "term": "population prospects",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        }
      ],
      "extract": "HIV transmission and case rates derived from studies (including household surveys) should be carefully reviewed to ensure that the following limitations do not apply: • They miss women outside of the PMTCT programme. • They miss vertical infections due to a woman seroconverting during pregnancy or breastfeeding. • They miss children who died between birth and the study reference period. • They miss mother–infant",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-033"
      ]
    },
    {
      "id": "page-034",
      "number": null,
      "title": "Page 34",
      "level": 1,
      "pageStart": 34,
      "pageEnd": 34,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 525,
      "summary": {
        "text": "Explains that Spectrum model estimates capture child HIV infections at population level, including among women outside programmes and those who seroconvert, but depend heavily on accurate data on pregnant women on and retained on ART. It then introduces the surveillance case definition for congenital syphilis, covering stillbirths and live births to inadequately treated seropositive mothers and children with clinical or laboratory evidence of infection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "syphilis serology",
          "heading": false
        },
        {
          "term": "stacked bar",
          "heading": false
        },
        {
          "term": "started art",
          "heading": false
        },
        {
          "term": "case definition",
          "heading": false
        },
        {
          "term": "surveillance case",
          "heading": false
        },
        {
          "term": "clinical case",
          "heading": false
        },
        {
          "term": "child hiv",
          "heading": false
        },
        {
          "term": "live birth",
          "heading": false
        }
      ],
      "extract": "16 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus The model estimates the number of children acquiring HIV during pregnancy, delivery or breastfeeding. The modelled estimates are captured at the population level and, thus, include new child infections that occurred among women not in the PMTCT programme or not attending health facilities. The Spectrum model also incorporates",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-034"
      ]
    },
    {
      "id": "page-035",
      "number": null,
      "title": "Page 35",
      "level": 1,
      "pageStart": 35,
      "pageEnd": 35,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 425,
      "summary": {
        "text": "Sets out why congenital syphilis is underreported, including limited laboratory and radiographic testing, unrecognized stillbirths and subtle clinical signs that require skilled providers. It explains the reasoning behind the surveillance case definition and the 2015 expert decision to use live births as the denominator, matching the HIV case rate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "surveillance case",
          "heading": false
        },
        {
          "term": "case rate",
          "heading": false
        },
        {
          "term": "case definition",
          "heading": false
        },
        {
          "term": "live births",
          "heading": false
        },
        {
          "term": "common adverse",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "infant",
          "heading": false
        },
        {
          "term": "care providers",
          "heading": false
        }
      ],
      "extract": "Box 3.5. \u0007Rationale for use of the surveillance case definition for CS CS is underreported for many reasons: • Laboratory and radiographic testing may not be available in some countries or clinical settings. • Congenital infections that result in spontaneous abortion or stillbirth may not be recognized or reported. Stillbirths are often not delivered in health facilities, and care providers may not realize that",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-035"
      ]
    },
    {
      "id": "page-036",
      "number": null,
      "title": "Page 36",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 36,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 438,
      "summary": {
        "text": "Lists the laboratory and radiographic findings consistent with congenital syphilis, from detection of Treponema pallidum and abnormal cerebrospinal fluid results to suggestive long-bone X-rays and infant serology titres compared with the mother's. It then introduces the WHO Congenital Syphilis Estimation Tool for estimating case rates and planning treatment scale-up where data are poor.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reactive non-treponemal",
          "heading": false
        },
        {
          "term": "non-treponemal serology",
          "heading": false
        },
        {
          "term": "serology titre",
          "heading": false
        },
        {
          "term": "unknown serology",
          "heading": false
        },
        {
          "term": "congenital syphilis",
          "heading": false
        },
        {
          "term": "clinical signs",
          "heading": false
        },
        {
          "term": "four-fold",
          "heading": false
        },
        {
          "term": "stillborn",
          "heading": false
        }
      ],
      "extract": "18 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Laboratory and radiographic evidence consistent with a diagnosis of CS includes any of the following: a. demonstration by dark-field microscopy or fluorescent antibody detection of Treponema pallidum in the umbilical cord, placenta, nasal discharge or skin lesion material or autopsy material of a neonate or stillborn infant; b.",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-036"
      ]
    },
    {
      "id": "page-037",
      "number": null,
      "title": "Page 37",
      "level": 1,
      "pageStart": 37,
      "pageEnd": 37,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 297,
      "summary": {
        "text": "Presents a figure on the main strengths of the WHO Congenital Syphilis Estimation Tool, such as estimating case rates and the benzathine penicillin needed. A box on managing maternal syphilis cites WHO screening and treatment guidance, defines adequate treatment and advises when to evaluate women for reinfection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "benzathine penicillin",
          "heading": false
        },
        {
          "term": "congenital syphilis",
          "heading": false
        },
        {
          "term": "maternal syphilis",
          "heading": false
        },
        {
          "term": "recommends benzathine",
          "heading": false
        },
        {
          "term": "syphilis screening",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "million units",
          "heading": false
        },
        {
          "term": "guideline recommends",
          "heading": false
        }
      ],
      "extract": "Fig. 3.1. \u0007Key strengths of the WHO Congenital Syphilis Estimation Tool Estimates case rates which is often difficult due to limited or no reporting Demonstrates prevention of congenital syphilis and adverse birth outcomes due to testing and treatment scale-up Evaluates progress which is needed to assess improvements in ANC-1 testing and treatment coverage targets Estimates amount of benzathine penicillin needed to",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-037",
        "library/10665-349550/blocks/figure-vfig-p037"
      ]
    },
    {
      "id": "page-038",
      "number": null,
      "title": "Page 38",
      "level": 1,
      "pageStart": 38,
      "pageEnd": 38,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 285,
      "summary": {
        "text": "Introduces the impact indicators for validating elimination of mother-to-child transmission of hepatitis B, aimed at preventing or minimizing vertical transmission. Countries with universal timely birth-dose vaccination must show HBsAg prevalence of 0.1% or less among children aged five and under, while those using a targeted birth dose must also show a transmission rate of 2% or less.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbsag prevalence",
          "heading": false
        },
        {
          "term": "year-old birth",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "prevalence among",
          "heading": false
        },
        {
          "term": "impact targets",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        }
      ],
      "extract": "20 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus 3.1.3. \u0007Impact indicators and targets for validation of EMTCT of HBV The goal of programmes for the EMTCT of HBV is to ensure that MTCT of hepatitis B is prevented or reduced to a very low level. To achieve validation of EMTCT of HBV, it is necessary to demonstrate the attainment of a set of impact and programmatic targets (Boxes",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-038"
      ]
    },
    {
      "id": "page-039",
      "number": null,
      "title": "Page 39",
      "level": 1,
      "pageStart": 39,
      "pageEnd": 39,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 466,
      "summary": {
        "text": "Explains the rationale for using HBsAg prevalence of 0.1% or less in young children as the hepatitis B impact target, since most chronic infections come from perinatal transmission and child prevalence is a proxy for incidence. It allows flexibility in age groups for serosurveys and notes that infants under nine months should not be tested because maternal antibodies cause false negatives.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pacific region",
          "heading": false
        },
        {
          "term": "hbsag prevalence",
          "heading": false
        },
        {
          "term": "european region",
          "heading": false
        },
        {
          "term": "western pacific",
          "heading": false
        },
        {
          "term": "year-old children",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "serosurveys",
          "heading": false
        }
      ],
      "extract": "Box 3.8. \u0007Rationale for HBV impact targets Universal HepB-BD: HBsAg prevalence ≤0.1% in ≤5-year-olds (and older children in certain circumstances) In the absence of preventive interventions, MTCT of HBV at the time of, or shortly after, birth accounts for most of the global burden of chronic hepatitis B infection (CHB) because about 90% of these perinatal infections lead to chronic infection. The prevalence of HBsAg",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-039"
      ]
    },
    {
      "id": "page-040",
      "number": null,
      "title": "Page 40",
      "level": 1,
      "pageStart": 40,
      "pageEnd": 40,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 405,
      "summary": {
        "text": "Explains the additional 2% hepatitis B transmission-rate target for countries using a targeted birth dose or with high-prevalence subpopulations, defining how the rate is calculated. It then introduces process indicators, requiring at least 95% coverage of first antenatal visits and of HIV and syphilis testing among pregnant women for at least two years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbv mtct",
          "heading": false
        },
        {
          "term": "targeted hepb-bd",
          "heading": false
        },
        {
          "term": "hbsag prevalence",
          "heading": false
        },
        {
          "term": "mtct target",
          "heading": false
        },
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "syphilis process",
          "heading": false
        },
        {
          "term": "process indicators",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        }
      ],
      "extract": "22 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Box 3.9. \u0007Rationale for HBV impact targets when provision of HepB-BD is targeted Targeted HepB-BD: HBsAg prevalence ≤0.1% in ≤5-year-olds and MTCT rate of ≤2% The HBV MTCT rate of ≤2% is an additional target for countries that provide targeted timely Hep B-BD or for countries with a low HBsAg prevalence but where there is still",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-040"
      ]
    },
    {
      "id": "page-041",
      "number": null,
      "title": "Page 41",
      "level": 1,
      "pageStart": 41,
      "pageEnd": 41,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 272,
      "summary": {
        "text": "Gives the rationale for near-universal HIV and syphilis testing in early pregnancy and for using pregnant women attending antenatal care as the denominator for syphilis testing coverage. It also covers lifelong ART for all women living with HIV and the 95% target for adequate treatment of syphilis-seropositive pregnant women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "attending anc",
          "heading": false
        },
        {
          "term": "syphilis testing",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "treatment coverage",
          "heading": false
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "prevent mtct",
          "heading": false
        },
        {
          "term": "service coverage",
          "heading": false
        }
      ],
      "extract": "Box 3.10. \u0007Rationale for maternal HIV and syphilis testing coverage Near-universal testing for HIV and syphilis in early pregnancy is necessary to identify women living with HIV who will benefit from services to prevent MTCT. Testing remains an entry point for providing prevention, treatment and care services to women for their own health as well as for their families and to prevent MTCT. ANC attendance and testing",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-041"
      ]
    },
    {
      "id": "page-042",
      "number": null,
      "title": "Page 42",
      "level": 1,
      "pageStart": 42,
      "pageEnd": 42,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 422,
      "summary": {
        "text": "Explains that syphilis treatment with benzathine penicillin at least 30 days before delivery is needed to prevent infant infection and mentions dual HIV/syphilis rapid tests. It lists the hepatitis B programme targets, including 90% coverage of infant vaccination, timely birth dose, antenatal HBsAg testing and antivirals for high-viral-load mothers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hepb-bd provision",
          "heading": false
        },
        {
          "term": "birth dose",
          "heading": false
        },
        {
          "term": "hepb vaccination",
          "heading": false
        },
        {
          "term": "hbsag-positive mothers",
          "heading": false
        },
        {
          "term": "syphilis treatment",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "vaccination coverage",
          "heading": false
        },
        {
          "term": "hepatitis vaccine",
          "heading": false
        }
      ],
      "extract": "24 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Box 3.13. Rationale for syphilis treatment coverage When treating seropositive pregnant women with at least one dose of intramuscular benzathine penicillin G, 30 days prior to delivery is the minimum time needed to prevent transmission of syphilis to the infant. Ideally, maternal treatment should be given in the first trimester,",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-042"
      ]
    },
    {
      "id": "page-043",
      "number": null,
      "title": "Page 43",
      "level": 1,
      "pageStart": 43,
      "pageEnd": 43,
      "labelStart": "25",
      "labelEnd": "25",
      "words": 480,
      "summary": {
        "text": "Sets out the rationale for hepatitis B programme targets, linking them to the global health sector strategy goals for vaccination, diagnosis and treatment. It explains that 90% coverage of the third infant dose and timely birth dose is expected to achieve the impact targets, and that high antenatal testing coverage matters mainly where the birth dose is targeted.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hepb-bd vaccination",
          "heading": false
        },
        {
          "term": "coverage targets",
          "heading": false
        },
        {
          "term": "programmatic targets",
          "heading": false
        },
        {
          "term": "coverage required",
          "heading": false
        },
        {
          "term": "hepb",
          "heading": false
        },
        {
          "term": "programme coverage",
          "heading": false
        },
        {
          "term": "impact targets",
          "heading": false
        },
        {
          "term": "vaccine action",
          "heading": false
        }
      ],
      "extract": "Box 3.14. \u0007Rationale for programmatic targets for EMTCT of HBV The GHSS on viral hepatitis sets programme coverage targets not only for the most important preventive interventions (≥90% of infants with three or more doses of vaccination and ≥90% of neonates who receive HepB-BD vaccination within 24 hours of birth), but also for diagnosis of 90% of people with HBV and ART for 90% of people with HBV who are eligible",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-043"
      ]
    },
    {
      "id": "page-044",
      "number": null,
      "title": "Page 44",
      "level": 1,
      "pageStart": 44,
      "pageEnd": 44,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 288,
      "summary": {
        "text": "Explains why the 90% antiviral coverage target for eligible HBsAg-positive pregnant women is lower than ART and syphilis treatment targets, as vaccination is the main tool against hepatitis B transmission. It also advises countries to monitor follow-up of exposed infants and notes that regions may add their own non-mandatory indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "emtct validation",
          "heading": false
        },
        {
          "term": "hbsag-positive pregnant",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        },
        {
          "term": "indicators",
          "heading": false
        },
        {
          "term": "antivirals",
          "heading": false
        },
        {
          "term": "pmtct",
          "heading": false
        }
      ],
      "extract": "26 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus The ≥90% coverage of use of antivirals in eligible HBsAg-positive pregnant women with a high HBV DNA level (>200 000 IU/mL) or hepatitis B e antigen (HBeAg) positivity is an additional indicator based on the 2020 WHO PMTCT recommendations for the use of antivirals in HBsAg-positive pregnant women (58). The treatment coverage",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-044"
      ]
    },
    {
      "id": "page-045",
      "number": null,
      "title": "Page 45",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 45,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 361,
      "summary": {
        "text": "Opens the chapter on foundational requirements for validation, stating that elimination requires quality diagnostics, prevention and treatment services, strong health information systems and respect for human rights, gender equality and community engagement. It begins the data system requirements, such as capturing public and non-public sector data, using standard case definitions and protecting privacy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "emtct validation",
          "heading": false
        },
        {
          "term": "foundational requirements",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "data quality",
          "heading": false
        },
        {
          "term": "quality assessment",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "outcome data",
          "heading": false
        },
        {
          "term": "exercises",
          "heading": false
        }
      ],
      "extract": "4. FOUNDATIONAL REQUIREMENTS OF EMTCT VALIDATION A standardized approach to providing evidence that demonstrates whether a country has achieved EMTCT of HIV, syphilis and HBV across a wide range of epidemiological and programmatic contexts goes beyond achievement of numerical targets. To achieve and maintain elimination, foundational requirements must ensure that quality diagnostics and primary prevention and",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-045"
      ]
    },
    {
      "id": "page-046",
      "number": null,
      "title": "Page 46",
      "level": 1,
      "pageStart": 46,
      "pageEnd": 46,
      "labelStart": "28",
      "labelEnd": "28",
      "words": 461,
      "summary": {
        "text": "Continues the data requirements, calling for subnational and subpopulation disaggregation and country assessment of data completeness, accuracy, consistency and timeliness with a dedicated verification tool. It then turns to laboratory quality, citing ISO 15189 standards and listing key requirements such as quality management, testing algorithms, quality control and external quality assessment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "laboratory quality",
          "heading": false
        },
        {
          "term": "data quality",
          "heading": false
        },
        {
          "term": "verification tool",
          "heading": false
        },
        {
          "term": "quality assessment",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "process indicators",
          "heading": false
        },
        {
          "term": "programme data",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        }
      ],
      "extract": "28 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus • make data available for national and subnational administrative units and disaggregation for relevant subpopulations (for example, adolescents, migrants, internally displaced, immigrants, non-citizen residents and indigenous/aboriginal populations). Similar to what is required for most other disease elimination or eradication",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-046"
      ]
    },
    {
      "id": "page-047",
      "number": null,
      "title": "Page 47",
      "level": 1,
      "pageStart": 47,
      "pageEnd": 47,
      "labelStart": "29",
      "labelEnd": "29",
      "words": 487,
      "summary": {
        "text": "Sets out what laboratories contributing surveillance and monitoring data must have, namely quality management systems, quality-assured test kits, trained staff and routine quality assurance with external assessment. It describes how the laboratory assessment reviews national testing algorithms and the suitability of the tests chosen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbv testing",
          "heading": false
        },
        {
          "term": "laboratory quality",
          "heading": false
        },
        {
          "term": "quality assurance",
          "heading": false
        },
        {
          "term": "eqa",
          "heading": false
        },
        {
          "term": "prequalification programme",
          "heading": false
        },
        {
          "term": "quality management",
          "heading": false
        },
        {
          "term": "international standards",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        }
      ],
      "extract": "Laboratories that contribute data to the surveillance and clinical monitoring systems should: [1] have a quality management system in place with sufficiently supportive leadership and governance; [2] ensure the quality of test kits and procedures: that tests are procured, stored and used according to international standards, such as WHO pre-qualification or other regulatory equivalent; [3] ensure the quality of",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-047"
      ]
    },
    {
      "id": "page-048",
      "number": null,
      "title": "Page 48",
      "level": 1,
      "pageStart": 48,
      "pageEnd": 48,
      "labelStart": "30",
      "labelEnd": "30",
      "words": 408,
      "summary": {
        "text": "Describes the remaining laboratory assessment areas, staff competence and laboratory data management, including timely return of results. It then outlines the programme assessment, which reviews national policies and guidelines, services in public and non-public sectors and the performance of low-coverage areas and subpopulations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "immunization programme",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "programme assessment",
          "heading": false
        },
        {
          "term": "national immunization",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "postpartum women",
          "heading": false
        },
        {
          "term": "birth dose",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        }
      ],
      "extract": "30 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus [3] Quality of testing. This is an assessment of staff competence in general through professional licensure as technologists or appropriate training of other health care workers as well as of staff proficiency in performing the tests used. [4] Laboratory data management. This is an assessment of the laboratory’s information",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-048"
      ]
    },
    {
      "id": "page-049",
      "number": null,
      "title": "Page 49",
      "level": 1,
      "pageStart": 49,
      "pageEnd": 49,
      "labelStart": "31",
      "labelEnd": "31",
      "words": 355,
      "summary": {
        "text": "Requires countries to show that services reach even the lowest-performing subnational units and least-served subpopulations. It introduces the requirement that programmes respect international standards on human rights, gender equality and community engagement, and lists assessment steps such as stakeholder interviews and consultations with women using services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lowest-performing subnational",
          "heading": false
        },
        {
          "term": "subnational units",
          "heading": false
        },
        {
          "term": "subnational administrative",
          "heading": false
        },
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "lowest coverage",
          "heading": false
        },
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "engagement assessment",
          "heading": false
        }
      ],
      "extract": "4.4. \u0007Human rights, gender equality and community engagement assessment A foundational requirement for validation of a country for eliminating vertical transmission of HIV, syphilis and HBV is that the programme and interventions must have been implemented in a manner that is consistent with international, regional and national standards on: • human rights 4.3.1. \u0007Assessment of low-performing units and of",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-049"
      ]
    },
    {
      "id": "page-050",
      "number": null,
      "title": "Page 50",
      "level": 1,
      "pageStart": 50,
      "pageEnd": 50,
      "labelStart": "32",
      "labelEnd": "32",
      "words": 391,
      "summary": {
        "text": "Notes that leaving no one behind and health equity are central to WHO strategies and that the hepatitis B component also adopts human rights, gender and community principles. It describes governments' obligations to respect, protect and fulfil rights, including sexual and reproductive health and rights, in preventing vertical transmission.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "prevent vertical",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "community engagement",
          "heading": false
        }
      ],
      "extract": "32 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus • gender equality • community engagement. The concepts of no one left behind and health equity are central to the WHO global health sector strategies and the broader WHO mission (10-12). Prevention of vertical transmission of HBV, new to this guidance, also values the principles of human rights, gender equality and community",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-050"
      ]
    },
    {
      "id": "page-051",
      "number": null,
      "title": "Page 51",
      "level": 1,
      "pageStart": 51,
      "pageEnd": 51,
      "labelStart": "33",
      "labelEnd": "33",
      "words": 464,
      "summary": {
        "text": "Explains how gender inequality and harmful norms can limit women's access to services and autonomy, making gender equality critical to preventing vertical transmission. It describes the assessment tool's markers and its three guiding questions on human rights, gender equality and meaningful engagement of affected women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "promoting gender",
          "heading": false
        },
        {
          "term": "meaningful engagement",
          "heading": false
        },
        {
          "term": "community engagement",
          "heading": false
        },
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "end vertical",
          "heading": false
        },
        {
          "term": "engagement assessment",
          "heading": false
        }
      ],
      "extract": "4.4.2. Gender equality Gender inequality and harmful gender norms and practices in a country can obstruct women’s exercise of their rights, including their sexual and reproductive health and rights. In the context of preventing vertical transmission of HIV, syphilis and HBV, promoting gender equality is critical, as it influences the opportunities that women and girls have to access relevant information and",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-051"
      ]
    },
    {
      "id": "page-052",
      "number": null,
      "title": "Page 52",
      "level": 1,
      "pageStart": 52,
      "pageEnd": 52,
      "labelStart": "34",
      "labelEnd": "34",
      "words": 440,
      "summary": {
        "text": "Explains that the qualitative assessment requires consultations with stakeholders, especially women who use the services and their networks, who can identify barriers and solutions. It states that assessors must have relevant expertise and involve people from networks of women with HIV alongside experts in human rights and gender.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "validation assessment",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "relevant health",
          "heading": false
        },
        {
          "term": "key stakeholders",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        }
      ],
      "extract": "34 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus The questions in the tool are qualitative in nature, and the data collection and assessment process necessarily involve consultations with a range of stakeholders, in particular with communities of women who use the relevant health services. Women who use the programmes know how current laws and policies affect their lives and how",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-052"
      ]
    },
    {
      "id": "page-053",
      "number": null,
      "title": "Page 53",
      "level": 1,
      "pageStart": 53,
      "pageEnd": 53,
      "labelStart": "35",
      "labelEnd": "35",
      "words": 276,
      "summary": {
        "text": "A table setting out the key steps, roles and responsible bodies for the human rights, gender equality and community engagement component of validation, from involving networks of women living with HIV and hepatitis B to holding a dialogue on findings and giving feedback.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "validation structures",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "community engagement",
          "heading": false
        },
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "national validation",
          "heading": false
        },
        {
          "term": "equality criteria",
          "heading": false
        },
        {
          "term": "focal point",
          "heading": false
        }
      ],
      "extract": "Table 4.1. \u0007Key steps for human rights, gender equality and community engagement in the validation assessment Phase Roles and responsibilities Responsible entity 1 Ensure that validation structures include representatives of networks of women living with HIV and HBV. National validation structures Review and understand the human rights, community engagement and gender equality criteria and tool. Select an",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-053",
        "library/10665-349550/blocks/table-003"
      ]
    },
    {
      "id": "page-054",
      "number": null,
      "title": "Page 54",
      "level": 1,
      "pageStart": 54,
      "pageEnd": 54,
      "labelStart": "36",
      "labelEnd": "36",
      "words": 376,
      "summary": {
        "text": "Explains that many sub-Saharan African countries cannot reach validation thresholds because high maternal HIV or syphilis prevalence keeps child case rates high even with low transmission rates. It opens the chapter on the path to elimination and lists the prevalence levels that make a country eligible to apply.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbv vaccination",
          "heading": false
        },
        {
          "term": "hbsag prevalence",
          "heading": false
        },
        {
          "term": "infant hbv",
          "heading": false
        },
        {
          "term": "maternal syphilis",
          "heading": false
        },
        {
          "term": "among year-olds",
          "heading": false
        },
        {
          "term": "hiv prevalence",
          "heading": false
        },
        {
          "term": "population prevalence",
          "heading": false
        },
        {
          "term": "pte",
          "heading": false
        }
      ],
      "extract": "Most countries in sub-Saharan Africa have reported a maternal HIV seroprevalence of >2% and a maternal syphilis seroprevalence of >1%. Many countries in East and Southern Africa have maternal HIV prevalence of >15%, with some as high as 25%. Even if the MTCT rate of <5% is reached, high HIV burden countries have been unable to achieve EMTCT validation due to their elevated HIV prevalence among pregnant women, which",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-054"
      ]
    },
    {
      "id": "page-055",
      "number": null,
      "title": "Page 55",
      "level": 1,
      "pageStart": 55,
      "pageEnd": 55,
      "labelStart": "37",
      "labelEnd": "37",
      "words": 366,
      "summary": {
        "text": "States that countries seeking certification on the path to elimination follow the same procedure as for validation. It begins a table of prevalence requirements, impact indicators and programme targets for each tier, with the bronze-tier targets for HIV, syphilis and hepatitis B.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "anc coverage",
          "heading": false
        },
        {
          "term": "births anc",
          "heading": false
        },
        {
          "term": "attending anc",
          "heading": false
        },
        {
          "term": "syphilis-seropositive pregnant",
          "heading": false
        },
        {
          "term": "anc treatment",
          "heading": false
        },
        {
          "term": "live births",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "hiv mtct",
          "heading": false
        }
      ],
      "extract": "5. \u0007Path to elimination: recognizing progress towards EMTCT in countries with a high burden of HIV, syphilis and HBV A country seeking certification on the PTE for HIV and syphilis follows the same procedure as a country requesting validation of EMTCT. See Chapter 7 and the Governance guidance for the validation of elimination of mother-to-child transmission of HIV and syphilis (14) for details on the validation",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-055",
        "library/10665-349550/blocks/table-004"
      ]
    },
    {
      "id": "page-056",
      "number": null,
      "title": "Page 56",
      "level": 1,
      "pageStart": 56,
      "pageEnd": 56,
      "labelStart": "38",
      "labelEnd": "38",
      "words": 509,
      "summary": {
        "text": "Continues the tier table with silver and gold requirements, such as transmission rates below 2% or 5% and paediatric case rates of 250 or fewer per 100,000 live births for the gold tier. It explains that moving up tiers brings a country closer to elimination and that the same principles apply to hepatitis B.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gold tier",
          "heading": false
        },
        {
          "term": "mtct rates",
          "heading": false
        },
        {
          "term": "high-burden countries",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "pte",
          "heading": false
        },
        {
          "term": "prevalence rates",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "service coverage",
          "heading": false
        }
      ],
      "extract": "38 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Tier Infection Impact indicators for at least one year Process/programme indicators for at least two years Gold tier HIV • \u0007MTCT of HIV rate of <2% in non-breastfeeding populations OR <5% in breastfeeding populations • \u0007A case rate of new paediatric HIV infections due to MTCT of ≤250 cases per 100 000 live births • \u0007≥95% ANC",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-056"
      ]
    },
    {
      "id": "page-057",
      "number": null,
      "title": "Page 57",
      "level": 1,
      "pageStart": 57,
      "pageEnd": 57,
      "labelStart": "39",
      "labelEnd": "39",
      "words": 359,
      "summary": {
        "text": "A table of scenarios linking antenatal HIV prevalence and a transmission rate below 5% to expected infant case rates and the applicable gold, silver or bronze tier, contrasted with full validation thresholds. It then begins describing why many countries face a high hepatitis B burden, including low birth-dose coverage and limited diagnostics.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbsag prevalence",
          "heading": false
        },
        {
          "term": "infant vaccination",
          "heading": false
        },
        {
          "term": "hepatitis vaccination",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "vaccination interventions",
          "heading": false
        },
        {
          "term": "hepb-bd",
          "heading": false
        },
        {
          "term": "pte",
          "heading": false
        },
        {
          "term": "mtct",
          "heading": false
        }
      ],
      "extract": "Table 5.2. \u0007Scenarios of prevalence, indicators and targets for certification on the PTE of MTCT of HIV HIV prevalence in ANC HIV MTCT rate Expected HIV infant case rate/100 000 Applicable tier Certification of PTE: for countries with strong programmes but high ANC prevalence, which makes it virtually impossible to achieve the case rate criterion for validation 5.0% <5.0 <250 Gold 7.0% <5.0 <350 Silver 9.0% <5.0",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-057",
        "library/10665-349550/blocks/table-005"
      ]
    },
    {
      "id": "page-058",
      "number": null,
      "title": "Page 58",
      "level": 1,
      "pageStart": 58,
      "pageEnd": 58,
      "labelStart": "40",
      "labelEnd": "40",
      "words": 441,
      "summary": {
        "text": "Explains the rationale for the hepatitis B path-to-elimination tiers, with bronze recognizing a universal timely birth-dose policy and higher tiers reflecting coverage milestones. It notes that hepatitis B path-to-elimination recognition is granted only at regional level unless the region asks for global recognition.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hepb-bd coverage",
          "heading": false
        },
        {
          "term": "pte",
          "heading": false
        },
        {
          "term": "towards elimination",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "tier",
          "heading": false
        },
        {
          "term": "progress towards",
          "heading": false
        },
        {
          "term": "recognizes",
          "heading": false
        },
        {
          "term": "global level",
          "heading": false
        }
      ],
      "extract": "40 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus Box 5.2. \u0007Rationale for the PTE for HBV A key principle is that each tier of the PTE represents a milestone in progress towards elimination, where validation of elimination is the ultimate goal. The indicators for PTE reflect the critical role of timely HepB-BD and infant vaccination in eliminating MTCT of HBV. • The bronze level",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-058"
      ]
    },
    {
      "id": "page-059",
      "number": null,
      "title": "Page 59",
      "level": 1,
      "pageStart": 59,
      "pageEnd": 59,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 404,
      "summary": {
        "text": "Opens the chapter on special populations and circumstances, noting that migrants, displaced people, indigenous people, adolescent girls and other vulnerable groups may face higher risk and poorer access to antenatal care. It also asks validation reports to describe the infant feeding choices and counselling offered to women living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vulnerable populations",
          "heading": false
        },
        {
          "term": "emtct services",
          "heading": false
        },
        {
          "term": "validation report",
          "heading": false
        },
        {
          "term": "national validation",
          "heading": false
        },
        {
          "term": "non-citizen",
          "heading": false
        },
        {
          "term": "breastfeeding",
          "heading": false
        },
        {
          "term": "care services",
          "heading": false
        },
        {
          "term": "migrants",
          "heading": false
        }
      ],
      "extract": "6.1. Special populations Most countries face challenges with delivery of health care services to members of key and vulnerable populations (including migrants, the internally displaced, immigrants, non-citizen residents, indigenous/aboriginal/First Nation people, members of other mobile populations and adolescent girls and young women). Women and their partners belonging to these groups may be at higher risk for",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-059"
      ]
    },
    {
      "id": "page-060",
      "number": null,
      "title": "Page 60",
      "level": 1,
      "pageStart": 60,
      "pageEnd": 60,
      "labelStart": "42",
      "labelEnd": "42",
      "words": 456,
      "summary": {
        "text": "Specifies infant HIV testing at 6–8 weeks and 18 months, or three months after breastfeeding ends, so that all infections are captured, including in non-breastfeeding settings. It introduces special considerations for small countries and island states, whose data should be verified by regional structures during country missions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation structures",
          "heading": false
        },
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "estimated data",
          "heading": false
        },
        {
          "term": "policy countries",
          "heading": false
        },
        {
          "term": "island",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        }
      ],
      "extract": "42 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus The national validation report should provide testing data for infants and HIV-exposed children at 6–8 weeks of age and at the end of 18 months (or three months after the end of breastfeeding, if longer than 18 months). This schedule should ensure that all possible cases of infants and young children who acquire HIV are captured",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-060"
      ]
    },
    {
      "id": "page-061",
      "number": null,
      "title": "Page 61",
      "level": 1,
      "pageStart": 61,
      "pageEnd": 61,
      "labelStart": "43",
      "labelEnd": "43",
      "words": 287,
      "summary": {
        "text": "Explains that regional and global committees may remove from the numerator infant cases judged not to be programme failures, after reviewing individual case reports. It asks countries with small numbers to provide case studies of exposed infants while preserving anonymity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation committee",
          "heading": false
        },
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "advisory committee",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "infant infection",
          "heading": false
        },
        {
          "term": "case",
          "heading": false
        },
        {
          "term": "determined",
          "heading": false
        },
        {
          "term": "occurred",
          "heading": false
        }
      ],
      "extract": "1. Cases determined not to be a failure of the programme or services. If cases are determined at the regional and global reviews not to result from failure of the programme or services, they may be removed from the numerator, with subsequent recalculation of screening and treatment coverage and case rates. Criteria for assessing these cases are as follows. • At the discretion of the regional validation committee",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-061"
      ]
    },
    {
      "id": "page-062",
      "number": null,
      "title": "Page 62",
      "level": 1,
      "pageStart": 62,
      "pageEnd": 62,
      "labelStart": "44",
      "labelEnd": "44",
      "words": 387,
      "summary": {
        "text": "A table showing how annual and four-year pooled HIV transmission and infant case rates vary in small countries with few pregnant women or cases. It adds that small countries may use the 2% hepatitis B transmission target, which requires high antenatal testing coverage.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "hiv mtct",
          "heading": false
        },
        {
          "term": "pooled infant",
          "heading": false
        },
        {
          "term": "case rate",
          "heading": false
        },
        {
          "term": "rate calculations",
          "heading": false
        },
        {
          "term": "year pooled",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "live births",
          "heading": false
        }
      ],
      "extract": "44 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus HIV MTCT rate for small countries Population case rate of new infant and young child HIV infections due to MTCT, or infant and young child case rate for syphilis for small countries Number of pregnant women with HIV in one year Number of infant cases in one year Annual MTCT rate (%) 4-year pooled MTCT rate (%)* Number of pregnant",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-062",
        "library/10665-349550/blocks/table-006"
      ]
    },
    {
      "id": "page-063",
      "number": null,
      "title": "Page 63",
      "level": 1,
      "pageStart": 63,
      "pageEnd": 63,
      "labelStart": "45",
      "labelEnd": "45",
      "words": 210,
      "summary": {
        "text": "Explains that PMTCT services provided by private, nongovernmental, faith-based and other non-public bodies should be included in national monitoring and reported together with public data. It adds that the programme assessment should compare access, delivery and payment in the non-public sector with the public sector.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non-public sectors",
          "heading": false
        },
        {
          "term": "non-public data",
          "heading": false
        },
        {
          "term": "public sector",
          "heading": false
        },
        {
          "term": "anc",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "emtct",
          "heading": false
        },
        {
          "term": "validation",
          "heading": false
        }
      ],
      "extract": "6.4. \u0007Assessing ANC EMTCT service coverage in non-public settings In addition to public sector health services, PMTCT services may be provided by private, nongovernmental organizations, faith-based organizations, non-health sector institutions, such as health services in correctional facilities and some other non-public entities. Ideally, national programme monitoring systems should include data from the non-public",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-063"
      ]
    },
    {
      "id": "page-064",
      "number": null,
      "title": "Page 64",
      "level": 1,
      "pageStart": 64,
      "pageEnd": 64,
      "labelStart": "46",
      "labelEnd": "46",
      "words": 485,
      "summary": {
        "text": "Opens the chapter on the validation process, emphasizing a public health approach that strengthens health systems while upholding rights, participation and gender equality. It advises countries to confirm they meet minimum criteria before applying and describes the national, regional and global teams that verify country reports using standard assessment tools.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "emtct validation",
          "heading": false
        },
        {
          "term": "validation committees",
          "heading": false
        },
        {
          "term": "validation structures",
          "heading": false
        },
        {
          "term": "validation process",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "secretariats",
          "heading": false
        },
        {
          "term": "syphilis",
          "heading": false
        }
      ],
      "extract": "Achieving EMTCT of HIV, syphilis and HBV requires a public health approach based on strengthening the health system to provide the maximum health benefit within the available resources while realizing rights to health, participation and gender equality. The validation approach sets the standards for quality and accessible interventions and services, with a focus on integration, person-centred care and community",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-064"
      ]
    },
    {
      "id": "page-065",
      "number": null,
      "title": "Page 65",
      "level": 1,
      "pageStart": 65,
      "pageEnd": 65,
      "labelStart": "47",
      "labelEnd": "47",
      "words": 439,
      "summary": {
        "text": "Describes guiding principles and partners in validation, including UN agencies such as UNAIDS, UNICEF and UNFPA, with the health ministry initiating the process. It begins the national-level steps, starting with the ministry's formal request letter sent through the WHO country office.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "emtct validation",
          "heading": false
        },
        {
          "term": "validation structures",
          "heading": false
        },
        {
          "term": "validation process",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        },
        {
          "term": "global levels",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "initiates",
          "heading": false
        },
        {
          "term": "pte",
          "heading": false
        }
      ],
      "extract": "7. The validation process 7.1.1. Key partners in validation of EMTCT Guiding principles for the process of validation of EMTCT of HIV, syphilis and HBV or progress on the PTE involve aligning the process with relevant national and global strategies and engaging relevant stakeholders in a multisectoral approach. Relevant United Nations partners, such as UNAIDS, UNICEF and UNFPA, and other international and national",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-065"
      ]
    },
    {
      "id": "page-066",
      "number": null,
      "title": "Page 66",
      "level": 1,
      "pageStart": 66,
      "pageEnd": 66,
      "labelStart": "48",
      "labelEnd": "48",
      "words": 418,
      "summary": {
        "text": "Lists further validation steps, including establishing a national validation committee, completing a preliminary assessment checklist and preparing the national report. It then describes regional review and the global review by the Global Validation Advisory Committee, which advises WHO whether the country should be validated or certified.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "validation committee",
          "heading": false
        },
        {
          "term": "validation secretariat",
          "heading": false
        },
        {
          "term": "validation team",
          "heading": false
        },
        {
          "term": "validation report",
          "heading": false
        },
        {
          "term": "national validation",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "validation assessment",
          "heading": false
        }
      ],
      "extract": "48 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus [2] Establishment of the national validation committee or national validation task force. The Ministry of Health establishes a national validation committee or task force and, optionally, a validation team or working group. [3] Completion of the preliminary assessment. The national validation committee, task force, team or working",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-066"
      ]
    },
    {
      "id": "page-067",
      "number": null,
      "title": "Page 67",
      "level": 1,
      "pageStart": 67,
      "pageEnd": 67,
      "labelStart": "49",
      "labelEnd": "49",
      "words": 392,
      "summary": {
        "text": "Describes the final step, in which the WHO Director-General signs a validation certificate sent with follow-up recommendations through the Regional Office. A figure summarizes the full validation and certification process and the responsibilities at national, regional and global levels.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation secretariat",
          "heading": false
        },
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "validation committee",
          "heading": false
        },
        {
          "term": "validation advisory",
          "heading": false
        },
        {
          "term": "validation report",
          "heading": false
        },
        {
          "term": "national validation",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "committee task",
          "heading": false
        }
      ],
      "extract": "[9] Official validation. If a country is successfully validated, the Director-General of WHO signs a certificate recognizing the candidate country’s achievement of validation of EMTCT. The certificate and recommendations for follow-up actions related to the validation review and for maintenance of EMTCT validation status accompany a letter from the Director General that is sent to the WHO Regional Office for",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-067",
        "library/10665-349550/blocks/figure-vfig-p067"
      ]
    },
    {
      "id": "page-068",
      "number": null,
      "title": "Page 68",
      "level": 1,
      "pageStart": 68,
      "pageEnd": 68,
      "labelStart": "50",
      "labelEnd": "50",
      "words": 338,
      "summary": {
        "text": "Opens the chapter on maintaining validation, explaining that sustained elimination needs monitoring and surveillance that track coverage and detect most cases, including in vulnerable groups. A table sets out the time intervals for maintenance reviews by country type and number of infections validated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "syphilis hbv",
          "heading": false
        },
        {
          "term": "hiv syphilis",
          "heading": false
        },
        {
          "term": "validation status",
          "heading": false
        },
        {
          "term": "triple years",
          "heading": false
        },
        {
          "term": "dual years",
          "heading": false
        },
        {
          "term": "maintenance review",
          "heading": false
        },
        {
          "term": "time intervals",
          "heading": false
        },
        {
          "term": "burden country",
          "heading": false
        }
      ],
      "extract": "The experience of elimination programmes has shown that, to sustain elimination of a disease at such a level that it is no longer a public health problem, a country requires a monitoring and surveillance system that can accurately assess intervention coverage and detect the majority of cases of MTCT of HIV, syphilis and HBV in a timely manner (including among vulnerable and key populations at risk of acquiring HIV",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-068",
        "library/10665-349550/blocks/table-007"
      ]
    },
    {
      "id": "page-069",
      "number": null,
      "title": "Page 69",
      "level": 1,
      "pageStart": 69,
      "pageEnd": 69,
      "labelStart": "51",
      "labelEnd": "51",
      "words": 493,
      "summary": {
        "text": "Describes how countries apply for maintenance of validation, with the global secretariat keeping the list of validated countries and scheduling reviews. Countries prepare reports using a template and should describe programme changes or disruptions, such as those caused by COVID-19 or natural disasters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation secretariat",
          "heading": false
        },
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "maintenance report",
          "heading": false
        },
        {
          "term": "validation committee",
          "heading": false
        },
        {
          "term": "maintenance review",
          "heading": false
        },
        {
          "term": "demonstrate maintenance",
          "heading": false
        },
        {
          "term": "report template",
          "heading": false
        },
        {
          "term": "global secretariat",
          "heading": false
        }
      ],
      "extract": "8. Maintenance of validation 8.1. \u0007Process of applying for maintenance of validation The global secretariat maintains a list of countries that have achieved validation and have maintained validation criteria and standards over time. The global secretariat is responsible for notifying regional-level structures of the maintenance review schedules for countries. Countries should prepare reports on maintenance of",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-069"
      ]
    },
    {
      "id": "page-070",
      "number": null,
      "title": "Page 70",
      "level": 1,
      "pageStart": 70,
      "pageEnd": 70,
      "labelStart": "52",
      "labelEnd": "52",
      "words": 478,
      "summary": {
        "text": "Describes what countries must submit when reporting on maintaining validation of elimination of mother-to-child transmission (EMTCT) of HIV, syphilis and hepatitis B, and how regional committees review these reports before passing them to the global secretariat. It also explains that after two global maintenance reviews, countries that keep meeting targets may be transferred to regional review, following a vote of the Global Validation Advisory Committee, with the option to revert to global review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "validation secretariat",
          "heading": false
        },
        {
          "term": "regional validation",
          "heading": false
        },
        {
          "term": "validation advisory",
          "heading": false
        },
        {
          "term": "validation committee",
          "heading": false
        },
        {
          "term": "global validation",
          "heading": false
        },
        {
          "term": "single validation",
          "heading": false
        },
        {
          "term": "regional level",
          "heading": false
        },
        {
          "term": "maintenance review",
          "heading": false
        }
      ],
      "extract": "52 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus [4] \u0007Responses to recommendations and updates on requests for information made by the Global Validation Advisory Committee in the previous review. The regional validation committee reviews the maintenance report to determine whether the country has maintained validation. The regional validation secretariat then submits the report",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-070"
      ]
    },
    {
      "id": "page-071",
      "number": null,
      "title": "Page 71",
      "level": 1,
      "pageStart": 71,
      "pageEnd": 71,
      "labelStart": "53",
      "labelEnd": "53",
      "words": 317,
      "summary": {
        "text": "The start of the reference list for the EMTCT validation criteria document, citing mainly WHO guidelines on HIV, hepatitis and syphilis, the 2030 Agenda and the 2021 UN political declaration on HIV and AIDS.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed august",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "eliminating mother",
          "heading": false
        },
        {
          "term": "geneva",
          "heading": false
        },
        {
          "term": "transmitted infections",
          "heading": false
        }
      ],
      "extract": "REFERENCES 1. \u0007Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 8 August 2021). 2. \u0007Consolidated guidelines on HIV testing services. Geneva: World Health Organization. (https://www.who.int/publications/i/item/978-92-4-155058-1,",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-071"
      ]
    },
    {
      "id": "page-072",
      "number": null,
      "title": "Page 72",
      "level": 1,
      "pageStart": 72,
      "pageEnd": 72,
      "labelStart": "54",
      "labelEnd": "54",
      "words": 364,
      "summary": {
        "text": "Continues the reference list, citing WHO governance guidance for EMTCT validation, UNAIDS global AIDS updates, WHO antiretroviral guidelines, research on maternal syphilis outcomes and a policy brief on dual HIV/syphilis rapid tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "aids update",
          "heading": false
        },
        {
          "term": "accessed april",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "joint united",
          "heading": false
        },
        {
          "term": "global aids",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "nations programme",
          "heading": false
        }
      ],
      "extract": "54 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus 14. \u0007Governance guidance for the validation of elimination of mother-to-child transmission of HIV and syphilis: an overview of structures and responsibilities at national, regional and global levels. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/hand le/10665/332488/9789240006614-eng.pdf?ua=1,",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-072"
      ]
    },
    {
      "id": "page-073",
      "number": null,
      "title": "Page 73",
      "level": 1,
      "pageStart": 73,
      "pageEnd": 73,
      "labelStart": "55",
      "labelEnd": "55",
      "words": 299,
      "summary": {
        "text": "Continues the reference list, citing work on congenital syphilis burden, WHO's hepatitis B vaccine position paper, principles of disease elimination and WHO pages on other elimination efforts such as leprosy, onchocerciasis, lymphatic filariasis, dracunculiasis and neonatal tetanus.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "accessed august",
          "heading": false
        },
        {
          "term": "mediacentre factsheets",
          "heading": false
        },
        {
          "term": "accessed september",
          "heading": false
        },
        {
          "term": "webpage",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "congenital syphilis",
          "heading": false
        }
      ],
      "extract": "26. \u0007Korenromp EL, Rowley J, Alonso M, Mello MB, Wijesooriya NS, Mahiané SG et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes— Estimates for 2016 and progress since 2012. PLOS ONE. 2019;14:e0211720. doi: 10.1371/ journal.pone.0211720. 27. \u0007World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 recommendations. Wkly Epidemiol Rec. 2017;92:369-92.",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-073"
      ]
    },
    {
      "id": "page-074",
      "number": null,
      "title": "Page 74",
      "level": 1,
      "pageStart": 74,
      "pageEnd": 74,
      "labelStart": "56",
      "labelEnd": "56",
      "words": 427,
      "summary": {
        "text": "Continues the reference list, citing WHO guidance on HIV and infant feeding, the UNAIDS Global Plan towards eliminating new HIV infections in children, Spectrum modelling, congenital syphilis strategy and regional hepatitis plans.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "western pacific",
          "heading": false
        },
        {
          "term": "gastroenterol hepatol",
          "heading": false
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "accessed september",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "pacific region",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        }
      ],
      "extract": "56 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus 40. \u0007Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV. Geneva: World Health Organization; 2016 (http://apps.who.int/iris/bitstre am/10665/246260/1/9789241549707-eng.pdf, accessed 24 March 2021). 41. \u0007Countdown to",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-074"
      ]
    },
    {
      "id": "page-075",
      "number": null,
      "title": "Page 75",
      "level": 1,
      "pageStart": 75,
      "pageEnd": 75,
      "labelStart": "57",
      "labelEnd": "57",
      "words": 361,
      "summary": {
        "text": "Continues the reference list, citing the Global Vaccine Action Plan, Immunization Agenda 2030, immunization coverage estimates, WHO hepatitis strategic information and prevention guidelines, and international guidelines on HIV and human rights.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed aug",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "accessed september",
          "heading": false
        },
        {
          "term": "handle eng",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        }
      ],
      "extract": "53. \u0007Global Vaccine Action Plan 2011–2020. Geneva: World Health Organization; 2013 (https:// www.who.int/teams/immunization-vaccines-and-biologicals/strategies/global-vaccine- action-plan, accessed 26 March 2021). 54. \u0007Immunization Agenda 2030: a global strategy to leave no one behind. Geneva: World Health Organization. (https://www.who.int/publications/m/item/immunization-agenda-2030-a-",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-075"
      ]
    },
    {
      "id": "page-076",
      "number": null,
      "title": "Page 76",
      "level": 1,
      "pageStart": 76,
      "pageEnd": 76,
      "labelStart": "58",
      "labelEnd": "58",
      "words": 345,
      "summary": {
        "text": "Continues the reference list, citing sources on human rights and gender equality in HIV, community engagement, Gavi's vaccine investment strategy, delivery care coverage and hepatitis B serosurveys.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "accessed september",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "joint united",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "nations programme",
          "heading": false
        },
        {
          "term": "policy brief",
          "heading": false
        }
      ],
      "extract": "58 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus 67. \u0007Human rights and health [webpage]. Geneva: World Health Organization; 2017 (https:// www.who.int/news-room/fact-sheets/detail/human-rights-and-health, accessed 14 July 2021). 68. \u0007Technical Brief. HIV, human rights, and gender equality. Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2019",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-076"
      ]
    },
    {
      "id": "page-077",
      "number": null,
      "title": "Page 77",
      "level": 1,
      "pageStart": 77,
      "pageEnd": 77,
      "labelStart": "59",
      "labelEnd": "59",
      "words": 93,
      "summary": {
        "text": "Ends the reference list with studies on hepatitis B control in Pacific island countries and the Spectrum modelling software.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "islands",
          "heading": false
        },
        {
          "term": "vaccine",
          "heading": false
        },
        {
          "term": "tokelau",
          "heading": false
        }
      ],
      "extract": "80. \u0007Patel MK, Wannemuehler K, Tairi R, Tutai R, Moturi E, Tabwaia B et al. Progress towards achieving hepatitis B control in the Cook Islands, Niue, Tokelau, and Kiribati. Vaccine. 2016;34:4298-303. doi: 10.1016/j.vaccine.2016.06.083 81. \u0007Breakwell L, Anga J, Cooley G, Ropiti L, Gwyn S, Wannemuehler K et al. Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-077"
      ]
    },
    {
      "id": "page-078",
      "number": null,
      "title": "Page 78",
      "level": 1,
      "pageStart": 78,
      "pageEnd": 78,
      "labelStart": "60",
      "labelEnd": "60",
      "words": 88,
      "summary": {
        "text": "Opens Annex 1 on clinical follow-up of infants and young children exposed to HIV, syphilis or hepatitis B, noting that HIV diagnosis in infants is complicated by assay limits, ongoing exposure and maternal antibodies, so follow-up must continue until final status is known.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "children exposed",
          "heading": false
        },
        {
          "term": "clinical follow-up",
          "heading": false
        }
      ],
      "extract": "A1.1. \u0007Clinical follow-up of infants and young children exposed to HIV The diagnosis of HIV infection in HIV-exposed infants and young children is complicated by the variable sensitivities of assays, ongoing HIV exposure (in utero, intrapartum and postpartum via breastfeeding) and the presence of maternal antibody for up to 12–15 months. For EMTCT, HIV- exposed infants and young children should be followed for an",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-078"
      ]
    },
    {
      "id": "page-079",
      "number": null,
      "title": "Page 79",
      "level": 1,
      "pageStart": 79,
      "pageEnd": 79,
      "labelStart": "61",
      "labelEnd": "61",
      "words": 431,
      "summary": {
        "text": "Presents WHO's simplified infant HIV diagnosis algorithm, with nucleic acid testing at set ages, prompt antiretroviral therapy with confirmatory retesting, and antibody testing at 18 months or three months after breastfeeding stops. The footnotes explain retesting to avoid false positives, extra testing for never-breastfed children and the continuing risk while breastfeeding lasts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "repeat nat",
          "heading": false
        },
        {
          "term": "conduct nat",
          "heading": false
        },
        {
          "term": "antibody testing",
          "heading": false
        },
        {
          "term": "infant child",
          "heading": false
        },
        {
          "term": "confirm infection",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "cessation",
          "heading": false
        },
        {
          "term": "start art",
          "heading": false
        }
      ],
      "extract": "Annex 1. \u0007Clinical follow-up of infants and young children exposed to HIV, syphilis or HBV Fig. A1. \u0007Simplified infant diagnosis algorithm from WHO’s Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (1) a The addition to the existing testing algorithm of NAT at birth can be considered. b Point-of-care NAT can be used to diagnose HIV infection as well as to confirm",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-079"
      ]
    },
    {
      "id": "page-080",
      "number": null,
      "title": "Page 80",
      "level": 1,
      "pageStart": 80,
      "pageEnd": 80,
      "labelStart": "62",
      "labelEnd": "62",
      "words": 508,
      "summary": {
        "text": "Sets out points on ruling out HIV in exposed infants, the role of nucleic acid testing and the need for high infant testing coverage, suggesting over 95% in small, low-prevalence countries and over 80% in high-prevalence ones. It also covers follow-up of syphilis-exposed infants and of hepatitis B-exposed infants, including post-vaccination serological testing as an extra indicator where only targeted birth-dose vaccination is given.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "infants born",
          "heading": false
        },
        {
          "term": "expect eid",
          "heading": false
        },
        {
          "term": "eid testing",
          "heading": false
        },
        {
          "term": "syphilis treatment",
          "heading": false
        },
        {
          "term": "clinical follow-up",
          "heading": false
        },
        {
          "term": "receive treatment",
          "heading": false
        },
        {
          "term": "infant outcomes",
          "heading": false
        }
      ],
      "extract": "62 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus • \u0007For HIV-exposed infants, ruling out HIV infection is based on the algorithm in Fig. A1 (1). • \u0007Nucleic acid testing is highly sensitive and specific to identify infection at any age. In infants it should be used to both diagnose and confirm infection (19, 21). • \u0007For HIV-exposed infants, high infant HIV testing coverage at",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-080"
      ]
    },
    {
      "id": "page-081",
      "number": null,
      "title": "Page 81",
      "level": 1,
      "pageStart": 81,
      "pageEnd": 81,
      "labelStart": "63",
      "labelEnd": "63",
      "words": 253,
      "summary": {
        "text": "Explains WHO advice to do post-vaccination serological testing one to two months after the last hepatitis B dose, noting it is not routinely needed but is useful in elimination contexts. It describes follow-up for infants who are infected, uninfected and protected, or uninfected but non-responders needing revaccination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbv vaccine",
          "heading": false
        },
        {
          "term": "vaccine series",
          "heading": false
        },
        {
          "term": "clinical follow-up",
          "heading": false
        },
        {
          "term": "infants",
          "heading": false
        },
        {
          "term": "hbsag-positive",
          "heading": false
        },
        {
          "term": "hepatitis",
          "heading": false
        },
        {
          "term": "responded",
          "heading": false
        },
        {
          "term": "uninfected",
          "heading": false
        }
      ],
      "extract": "The WHO policy on hepatitis B vaccination recommends that, where needed, PVST in exposed infants should be carried out at least 1–2 months after administration of the last dose of the hepatitis B vaccine series, when the antibody response is greatest (27). Routine PSVT testing for immunity (anti-HBs) is not necessary, as the primary 3-dose series induces protective antibody concentrations in >95% of healthy infants,",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-081"
      ]
    },
    {
      "id": "page-082",
      "number": null,
      "title": "Page 82",
      "level": 1,
      "pageStart": 82,
      "pageEnd": 82,
      "labelStart": "64",
      "labelEnd": "64",
      "words": 408,
      "summary": {
        "text": "Opens Annex 2 on measuring indicators for validating elimination of mother-to-child transmission of hepatitis B, recommending national serosurveys of HBsAg prevalence in children aged five and under as the gold standard. It discusses the trade-offs of different age ranges and options to reduce cost, such as targeting higher-prevalence groups or multiphase survey designs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hbsag prevalence",
          "heading": false
        },
        {
          "term": "serosurveys",
          "heading": false
        },
        {
          "term": "year-olds",
          "heading": false
        },
        {
          "term": "age range",
          "heading": false
        },
        {
          "term": "horizontal transmission",
          "heading": false
        },
        {
          "term": "preferred approach",
          "heading": false
        },
        {
          "term": "biomarker",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        }
      ],
      "extract": "ANNEX 2. \u0007MEASUREMENT OF INDICATORS AND TARGETS FOR VALIDATION OF EMTCT OF HEPATITIS B VIRUS A2.1. \u0007Measurement of childhood prevalence of HBsAg in ≤5-year-olds A2.1.1. \u0007Preferred approach: measurement of childhood HBsAg prevalence in ≤5-year-olds The preferred approach is to directly measure a proxy for chronic HBV incidence (that is, HBsAg prevalence in ≤5-year-olds) with national-level biomarker surveys among",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-082"
      ]
    },
    {
      "id": "page-083",
      "number": null,
      "title": "Page 83",
      "level": 1,
      "pageStart": 83,
      "pageEnd": 83,
      "labelStart": "65",
      "labelEnd": "65",
      "words": 330,
      "summary": {
        "text": "Adds the option of integrating hepatitis B testing into existing national surveys and notes that small Pacific island countries can use a finite population correction when sizing serosurveys. It then describes measuring a mother-to-child transmission rate of 2% or less through follow-up of exposed infants in settings with targeted birth-dose vaccination, which requires strong data systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtct rate",
          "heading": false
        },
        {
          "term": "prevalence countries",
          "heading": false
        },
        {
          "term": "sample size",
          "heading": false
        },
        {
          "term": "fpc",
          "heading": false
        },
        {
          "term": "pvst",
          "heading": false
        },
        {
          "term": "infants",
          "heading": false
        },
        {
          "term": "hepb-bd",
          "heading": false
        },
        {
          "term": "hbsag",
          "heading": false
        }
      ],
      "extract": "Annex 2. \u0007Measurement of indicators and targets for validation of EMTCT of hepatitis B virus 3) \u0007integrate into existing national surveys for other disease areas (which are often performed using dried blood spot testing), such as the Demographic and Health Surveys and AIDS Indicator Surveys. For countries with a small population size, such as the islands in the Pacific, their size need not be a hindrance to",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-083"
      ]
    },
    {
      "id": "page-084",
      "number": null,
      "title": "Page 84",
      "level": 1,
      "pageStart": 84,
      "pageEnd": 84,
      "labelStart": "66",
      "labelEnd": "66",
      "words": 395,
      "summary": {
        "text": "Explains that mathematical modelling can complement, but not replace, empirical data in judging whether hepatitis B elimination targets are met, and should use independent, peer-reviewed models. It lists uses such as setting country-specific coverage targets, designing biomarker surveys and converting prevalence into incidence estimates, noting standards comparable to Spectrum for HIV are still to be set.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mathematical models",
          "heading": false
        },
        {
          "term": "biomarker survey",
          "heading": false
        },
        {
          "term": "programmatic data",
          "heading": false
        },
        {
          "term": "programmatic coverage",
          "heading": false
        },
        {
          "term": "empirical data",
          "heading": false
        },
        {
          "term": "incidence rate",
          "heading": false
        },
        {
          "term": "elimination",
          "heading": false
        },
        {
          "term": "whole population",
          "heading": false
        }
      ],
      "extract": "66 Criteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus 1 \u0007Mathematical models employed in the process should be independent and peer reviewed, as the regional validation task force will review inputs, assumptions, analysis and outputs in detail during its review of the national validation report. In addition, the models used might vary across countries. A2.2. \u0007Using mathematical",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-084"
      ]
    },
    {
      "id": "page-085",
      "number": null,
      "title": "Page 85",
      "level": 1,
      "pageStart": 85,
      "pageEnd": 85,
      "labelStart": "67",
      "labelEnd": "67",
      "words": 123,
      "summary": {
        "text": "Lists the web annexes of the EMTCT validation guidance to be published in 2022, including assessment checklists, report templates, data, laboratory and programme verification tools, and human rights and community engagement tools.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "verification tool",
          "heading": false
        },
        {
          "term": "web annexes",
          "heading": false
        },
        {
          "term": "gender equality",
          "heading": false
        },
        {
          "term": "report template",
          "heading": false
        }
      ],
      "extract": "The following web annexes will be published in 2022. The current tools can be found at: https:// www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv- syphilis-and-hepatitis-b/validation/process-and-tools. Web Annex A. \u0007Checklist for preliminary assessment of EMTCT validation Web Annex B. \u0007Congenital syphilis estimation tool Web Annex C. \u0007Initial validation or Path to",
      "extractCut": true,
      "blocks": [
        "library/10665-349550/blocks/prose-page-085"
      ]
    },
    {
      "id": "page-086",
      "number": null,
      "title": "Page 86",
      "level": 1,
      "pageStart": 86,
      "pageEnd": 86,
      "labelStart": "68",
      "labelEnd": "68",
      "words": 20,
      "summary": {
        "text": "The back cover, giving contact details for the WHO Department of HIV/AIDS in Geneva.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int www.who.int/hiv",
      "extractCut": false,
      "blocks": [
        "library/10665-349550/blocks/prose-page-086"
      ]
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 8,
        "items": [
          "FOREWORD iv 6.  GUIDANCE ON SPECIAL POPULATIONS",
          "GLOSSARY x 6.2.  SELECTING TARGETS FOR EMTCT OF HIV",
          "TRIPLE ELIMINATION OF MOTHER-TO-CHILD 3 6.4.  ASSESSING ANC EMTCT SERVICE",
          "AND PROCESSES FOR EMTCT OF HIV, SYPHILIS AND HBV 7.2. STEPS IN THE VALIDATION PROCESS",
          "QUALIFYING REQUIREMENTS FOR EMTCT 7 8. MAINTENANCE OF VALIDATION",
          "OF HIV, SYPHILIS AND HBV 8.1.  PROCESS OF APPLYING FOR",
          "PROCESS INDICATORS FOR VALIDATION 22 A1.1.  CLINICAL FOLLOW-UP OF INFANTS AND",
          "PROGRESS TOWARDS EMTCT IN COUNTRIES WEB ANNEXES"
        ]
      },
      "found_not_listed": {
        "count": 24,
        "items": [
          "1.1 \u0007Mother-to-child transmission in the HIV, syphilis and HBV epidemics",
          "1.2 \u0007Triple elimination of mother-to-child transmission and its validation",
          "2.1 \u0007Qualifying requirements for EMTCT of HIV, syphilis and HBV",
          "2 RATIONALE FOR STANDARDIZED CRITERIA AND PROCESSES FOR EMTCT OF HIV, SYPHILIS AND HBV",
          "2.2 \u0007Standardized criteria used in EMTCT of HIV, syphilis and HBV",
          "3 INDICATORS AND TARGETS FOR VALIDATION OF EMTCT OF HIV, SYPHILIS AND HBV",
          "3.1 \u0007Impact indicators and targets for validation of EMTCT",
          "3.2 \u0007Process indicators for validation of EMTCT of HIV, syphilis and HBV",
          "4 FOUNDATIONAL REQUIREMENTS OF EMTCT VALIDATION",
          "4.1 Data quality assessment",
          "4.3 Programme assessment",
          "4.4 \u0007Human rights, gender equality and community engagement assessment",
          "5 \u0007PATH TO ELIMINATION: RECOGNIZING PROGRESS TOWARDS EMTCT IN COUNTRIES WITH A HIGH BURDEN OF HIV, SYPHILIS AND HBV",
          "5.1 Rationale for selecting criteria for the PTE",
          "6.1 Special populations",
          "6.2 \u0007Selecting targets for EMTCT of HIV in breastfeeding and nonbreastfeeding populations",
          "6 GUIDANCE ON SPECIAL POPULATIONS AND SPECIAL CIRCUMSTANCES",
          "6.3 \u0007Countries with small numbers of HIV-, syphilis- and HBV-positive pregnant women",
          "1 Cases determined not to be a failure of the programme or services. If cases are",
          "6.4 \u0007Assessing ANC EMTCT service coverage in non-public settings",
          "7.1 Validation structures",
          "7.2 Steps in the validation process",
          "8 MAINTENANCE OF VALIDATION",
          "8.1 \u0007Process of applying for maintenance of validation"
        ]
      },
      "page_mismatch": {
        "count": 7,
        "items": [
          "ACKNOWLEDGEMENTS vi AND SPECIAL CIRCUMSTANCES ESSENTIAL WHO EMTCT RESOURCES viii 6.1. SPECIAL POPULATIONS: listed p59, found p9",
          "INTRODUCTION 1 6.3.  COUNTRIES WITH SMALL NUMBERS OF: listed p60, found p23",
          "RATIONALE FOR STANDARDIZED CRITERIA 7 7.1. VALIDATION STRUCTURES: listed p64, found p25",
          "INDICATORS AND TARGETS FOR VALIDATION 10 ANNEXES: listed p78, found p82",
          "FOUNDATIONAL REQUIREMENTS OF EMTCT 27 ANNEX 2.  MEASUREMENT OF INDICATORS: listed p82, found p45",
          "LABORATORY QUALITY ASSESSMENT 28 A2.1.  MEASUREMENT OF CHILDHOOD: listed p82, found p46",
          "HUMAN RIGHTS, GENDER EQUALITY 31 A2.2.  USING MATHEMATICAL MODELLING: listed p84, found p50"
        ]
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 14,
      "items": [
        "p5: pdf-labels 5, printed iii",
        "p6: pdf-labels 6, printed iv",
        "p7: pdf-labels 7, printed v",
        "p8: pdf-labels 8, printed vi",
        "p9: pdf-labels 9, printed vii",
        "p10: pdf-labels 10, printed viii",
        "p11: pdf-labels 11, printed ix, contents ix",
        "p12: pdf-labels 12, printed x",
        "p13: pdf-labels 13, printed xi",
        "p14: pdf-labels 14, printed xii",
        "p15: pdf-labels 15, printed xiii",
        "p16: pdf-labels 16, printed xiv",
        "p17: pdf-labels 17, printed xv",
        "p18: pdf-labels 18, printed xvi"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "hbv validation",
      "heading": true
    },
    {
      "term": "syphilis hbv",
      "heading": false
    },
    {
      "term": "emtct validation",
      "heading": true
    },
    {
      "term": "hiv syphilis",
      "heading": true
    },
    {
      "term": "hbv elimination",
      "heading": false
    },
    {
      "term": "hbv mtct",
      "heading": false
    },
    {
      "term": "hbv transmission",
      "heading": false
    },
    {
      "term": "validation targets",
      "heading": true
    },
    {
      "term": "global validation",
      "heading": false
    },
    {
      "term": "validation criteria",
      "heading": false
    },
    {
      "term": "regional validation",
      "heading": false
    },
    {
      "term": "infant hbv",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "1",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "3",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "xiv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 17,
      "label": "xv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 18,
      "label": "xvi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "20",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "30",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "32",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "36",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 55,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "38",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 57,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "41",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "42",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "44",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "46",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 65,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 66,
      "label": "48",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 68,
      "label": "50",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "51",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 70,
      "label": "52",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 71,
      "label": "53",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 72,
      "label": "54",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 73,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 74,
      "label": "56",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 75,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 76,
      "label": "58",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 77,
      "label": "59",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 78,
      "label": "60",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 79,
      "label": "61",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 80,
      "label": "62",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 81,
      "label": "63",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 82,
      "label": "64",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 83,
      "label": "65",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 84,
      "label": "66",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 85,
      "label": "67",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 86,
      "label": "68",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "\u0007Summary of impact and process/programmatic targets",
      "page": 17,
      "pageLabel": "xv",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "1.1",
      "title": "\u0007Terminology",
      "page": 19,
      "pageLabel": "1",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "1.2",
      "title": "What’s new in the third version",
      "page": 23,
      "pageLabel": "5",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3.1",
      "title": "\u0007Country options for applications for single, dual or",
      "page": 28,
      "pageLabel": "10",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.1",
      "title": "\u0007Summary of required impact and process targets for",
      "page": 29,
      "pageLabel": "11",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.2",
      "title": "\u0007Calculation of population case rate and MTCT rate",
      "page": 31,
      "pageLabel": "13",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.3",
      "title": "\u0007Rationale for use of a case rate of new paediatric",
      "page": 32,
      "pageLabel": "14",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.4",
      "title": "\u0007Using and understanding Spectrum HIV estimates",
      "page": 33,
      "pageLabel": "15",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.5",
      "title": "\u0007Rationale for use of the surveillance case",
      "page": 35,
      "pageLabel": "17",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "3.1",
      "title": "\u0007Key strengths of the WHO Congenital Syphilis",
      "page": 37,
      "pageLabel": "19",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "3.6",
      "title": "\u0007Management of maternal syphilis",
      "page": 37,
      "pageLabel": "19",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.7",
      "title": "\u0007Impact targets for validation of EMTCT of HBV",
      "page": 38,
      "pageLabel": "20",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.8",
      "title": "\u0007Rationale for HBV impact targets",
      "page": 39,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.9",
      "title": "\u0007Rationale for HBV impact targets when provision of",
      "page": 40,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.10",
      "title": "\u0007Rationale for maternal HIV and syphilis testing",
      "page": 41,
      "pageLabel": "23",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.11",
      "title": "\u0007Rationale for use of the denominator of pregnant",
      "page": 41,
      "pageLabel": "23",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.12",
      "title": "\u0007Rationale for HIV treatment coverage",
      "page": 41,
      "pageLabel": "23",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.13",
      "title": "Rationale for syphilis treatment coverage",
      "page": 42,
      "pageLabel": "24",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3.14",
      "title": "\u0007Rationale for programmatic targets for EMTCT",
      "page": 43,
      "pageLabel": "25",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4.1",
      "title": "\u0007Key requirements for data quality assessment",
      "page": 45,
      "pageLabel": "27",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4.2",
      "title": "\u0007Key requirements for laboratory quality assessment",
      "page": 46,
      "pageLabel": "28",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4.3",
      "title": "\u0007Key requirements for EMTCT programme assessment",
      "page": 48,
      "pageLabel": "30",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4.4",
      "title": "\u0007Key requirements for human rights, gender equality",
      "page": 49,
      "pageLabel": "31",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4.5",
      "title": "\u0007Who should be engaged in the assessment?",
      "page": 52,
      "pageLabel": "34",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4.1",
      "title": "\u0007Key steps for human rights, gender equality and",
      "page": 53,
      "pageLabel": "35",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "5.1",
      "title": "\u0007Country prevalence requirements for eligibility",
      "page": 54,
      "pageLabel": "36",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.1",
      "title": "\u0007Prevalence requirements, indicators and targets for",
      "page": 55,
      "pageLabel": "37",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.2",
      "title": "\u0007Scenarios of prevalence, indicators and targets",
      "page": 57,
      "pageLabel": "39",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "5.2",
      "title": "\u0007Rationale for the PTE for HBV",
      "page": 58,
      "pageLabel": "40",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "6.1",
      "title": "\u0007Targets depending on country breastfeeding policies",
      "page": 60,
      "pageLabel": "42",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.1",
      "title": "\u0007Scenarios for HIV MTCT rate and infant case rate of HIV",
      "page": 62,
      "pageLabel": "44",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "7.1",
      "title": "\u0007Process for validation of EMTCT or PTE certification,",
      "page": 67,
      "pageLabel": "49",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "8.1",
      "title": "\u0007Time intervals for assessing maintenance of validation",
      "page": 68,
      "pageLabel": "50",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "A1",
      "title": "\u0007Simplified infant diagnosis algorithm from WHO’s",
      "page": 79,
      "pageLabel": "61",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p037",
      "file": "figures/vfig-p037.webp",
      "page": 37,
      "shows": [
        "Figure 3.1",
        "Box 3.6"
      ],
      "narratives": {
        "en": "A page showing Fig. 3.1, “Key strengths of the WHO Congenital Syphilis Estimation Tool”, a circle with four numbered points: 1 estimates case rates, which is often difficult due to limited or no reporting; 2 evaluates progress needed to assess improvements in ANC-1 testing and treatment coverage targets; 3 estimates the amount of benzathine penicillin needed to treat maternal syphilis and prevent congenital syphilis; 4 demonstrates prevention of congenital syphilis and adverse birth outcomes due to testing and treatment scale-up. Below is Box 3.6, “Management of maternal syphilis”, a text box with WHO treatment recommendations.",
        "ar": "صفحة تعرض الشكل 3.1 «نقاط القوة الرئيسية لأداة المنظمة لتقدير الزهري الخلقي»، وهو دائرة بأربع نقاط مرقّمة: 1 تقدّر معدلات الحالات، وهو أمر صعب غالباً بسبب محدودية الإبلاغ أو انعدامه؛ 2 تقيّم التقدم اللازم لتقييم التحسّن في غايات تغطية الاختبار والعلاج في زيارة الرعاية السابقة للولادة الأولى؛ 3 تقدّر كمية البنزاثين بنسلين اللازمة لعلاج الزهري لدى الأمهات والوقاية من الزهري الخلقي؛ 4 تبيّن الوقاية من الزهري الخلقي ومن الحصائل الضائرة للولادة بفضل التوسّع في الاختبار والعلاج. وفي الأسفل الإطار 3.6 «تدبير الزهري لدى الأمهات»، وهو إطار نصي يتضمن توصيات المنظمة بشأن العلاج.",
        "zh": "该页显示图3.1“世卫组织先天梅毒估算工具的主要优势”，为一个带有四个编号要点的圆圈：1 估算病例率，而由于报告有限或缺失，这通常很困难；2 评价进展，以评估首次产前检查检测和治疗覆盖率目标的改善情况；3 估算治疗孕产妇梅毒和预防先天梅毒所需的苄星青霉素数量；4 证明扩大检测和治疗可预防先天梅毒和不良出生结局。下方为框3.6“孕产妇梅毒的管理”，是一个包含世卫组织治疗建议的文字框。",
        "es": "Página que muestra la Fig. 3.1, «Principales puntos fuertes de la herramienta de la OMS para estimar la sífilis congénita», un círculo con cuatro puntos numerados: 1 estima las tasas de casos, algo a menudo difícil por la notificación limitada o inexistente; 2 evalúa el progreso necesario para valorar las mejoras en las metas de cobertura de pruebas y tratamiento en la primera consulta prenatal; 3 estima la cantidad de penicilina benzatínica necesaria para tratar la sífilis materna y prevenir la sífilis congénita; 4 demuestra la prevención de la sífilis congénita y de los resultados adversos del parto gracias a la ampliación de las pruebas y el tratamiento. Debajo figura el Recuadro 3.6, «Manejo de la sífilis materna», con las recomendaciones de tratamiento de la OMS.",
        "fr": "Page présentant la Fig. 3.1, « Principaux atouts de l’outil de l’OMS pour l’estimation de la syphilis congénitale », un cercle comportant quatre points numérotés : 1 estime les taux de cas, souvent difficiles à obtenir faute de notification ou en raison d’une notification limitée ; 2 évalue les progrès nécessaires pour apprécier l’amélioration des cibles de couverture du dépistage et du traitement lors de la première consultation prénatale ; 3 estime la quantité de benzathine pénicilline nécessaire pour traiter la syphilis maternelle et prévenir la syphilis congénitale ; 4 démontre la prévention de la syphilis congénitale et des issues défavorables de la naissance grâce à l’intensification du dépistage et du traitement. En dessous figure l’Encadré 3.6, « Prise en charge de la syphilis maternelle », avec les recommandations de traitement de l’OMS.",
        "ru": "Страница с Рис. 3.1 «Основные преимущества инструмента ВОЗ для оценки врождённого сифилиса» — кругом с четырьмя пронумерованными пунктами: 1 — оценивает показатели заболеваемости, что часто затруднено из-за ограниченной отчётности или её отсутствия; 2 — оценивает прогресс, необходимый для определения улучшений в достижении целевых показателей охвата тестированием и лечением при первом дородовом посещении; 3 — оценивает количество бензатин-пенициллина, необходимого для лечения сифилиса у матерей и профилактики врождённого сифилиса; 4 — демонстрирует профилактику врождённого сифилиса и неблагоприятных исходов родов благодаря расширению тестирования и лечения. Ниже — Вставка 3.6 «Ведение сифилиса у матерей» с рекомендациями ВОЗ по лечению."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p067",
      "file": "figures/vfig-p067.webp",
      "page": 67,
      "shows": [
        "Figure 7.1"
      ],
      "narratives": {
        "en": "A page showing Fig. 7.1, “Process for validation of EMTCT or PTE certification, including the responsibilities of the health ministry, committees and secretariats at the national, regional and global levels”. Four rows, each with a chevron label, list nine numbered steps: the health ministry requests validation and establishes a national validation committee (steps 1–2); the national committee or task force conducts a preliminary assessment and submits a national report (3–4); the regional validation committee and secretariat review it and submit a regional report (5–7); and the Global Validation Advisory Committee reviews the report, after which the WHO Director-General signs a certificate (8–9).",
        "ar": "صفحة تعرض الشكل 7.1 «عملية التحقق من القضاء على انتقال العدوى من الأم إلى الطفل أو الإشهاد على المسار نحو القضاء، بما في ذلك مسؤوليات وزارة الصحة واللجان والأمانات على المستويات الوطني والإقليمي والعالمي». تعرض أربعة صفوف، لكل منها تسمية على شكل سهم، تسع خطوات مرقّمة: تطلب وزارة الصحة التحقق وتنشئ لجنة وطنية للتحقق (الخطوتان 1–2)؛ وتجري اللجنة الوطنية أو فرقة العمل تقييماً أولياً وتقدّم تقريراً وطنياً (3–4)؛ وتستعرضه لجنة التحقق الإقليمية وأمانتها وتقدّم تقريراً إقليمياً (5–7)؛ وتستعرض اللجنة الاستشارية العالمية للتحقق التقرير، ثم يوقّع المدير العام للمنظمة شهادة (8–9).",
        "zh": "该页显示图7.1“消除母婴传播验证或迈向消除路径认证的流程，包括卫生部以及国家、区域和全球层面委员会和秘书处的职责”。四行内容各配有一个箭头形标签，列出九个编号步骤：卫生部申请验证并成立国家验证委员会（步骤1–2）；国家委员会或工作组进行初步评估并提交国家报告（3–4）；区域验证委员会和秘书处审查后提交区域报告（5–7）；全球验证咨询委员会审查报告，随后世卫组织总干事签署证书（8–9）。",
        "es": "Página que muestra la Fig. 7.1, «Proceso de validación de la ETMI o de certificación de la vía hacia la eliminación, incluidas las responsabilidades del ministerio de salud y de los comités y secretarías a nivel nacional, regional y mundial». Cuatro filas, cada una con una etiqueta en forma de cheurón, enumeran nueve pasos: el ministerio de salud solicita la validación y crea un comité nacional de validación (pasos 1–2); el comité o grupo de trabajo nacional realiza una evaluación preliminar y presenta un informe nacional (3–4); el comité regional de validación y su secretaría lo examinan y presentan un informe regional (5–7); y el Comité Asesor Mundial de Validación examina el informe, tras lo cual el Director General de la OMS firma un certificado (8–9).",
        "fr": "Page présentant la Fig. 7.1, « Processus de validation de l’ETME ou de certification du parcours vers l’élimination, y compris les responsabilités du ministère de la santé, des comités et des secrétariats aux niveaux national, régional et mondial ». Quatre rangées, chacune avec une étiquette en chevron, énumèrent neuf étapes : le ministère de la santé demande la validation et crée un comité national de validation (étapes 1–2) ; le comité ou groupe de travail national procède à une évaluation préliminaire et soumet un rapport national (3–4) ; le comité régional de validation et son secrétariat l’examinent et soumettent un rapport régional (5–7) ; et le Comité consultatif mondial de validation examine le rapport, après quoi le Directeur général de l’OMS signe un certificat (8–9).",
        "ru": "Страница с Рис. 7.1 «Процесс валидации ЭПМР или сертификации пути к элиминации, включая обязанности министерства здравоохранения, комитетов и секретариатов на национальном, региональном и глобальном уровнях». В четырёх строках, каждая с меткой в виде шеврона, перечислены девять шагов: министерство здравоохранения запрашивает валидацию и создаёт национальный комитет по валидации (шаги 1–2); национальный комитет или рабочая группа проводит предварительную оценку и представляет национальный доклад (3–4); региональный комитет по валидации и секретариат рассматривают его и представляют региональный доклад (5–7); Глобальный консультативный комитет по валидации рассматривает доклад, после чего Генеральный директор ВОЗ подписывает сертификат (8–9)."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Summary of impact and process/programmatic targets for EMTCT of HIV, syphilis and HBV",
      "pages": [
        17
      ],
      "columns": [
        {
          "titles": "Elimination targets"
        },
        {
          "titles": "HIV EMTCT"
        },
        {
          "titles": "Syphilis EMTCT"
        },
        {
          "titles": "HBV EMTCT"
        }
      ],
      "rows": [
        [
          "2030 WHO GHSS (8, 10, 11) and UNGA political declaration (13) aspirational targets",
          "Zero new infections among infants and young children and achievement of the 95-95-95 targets",
          "≤50 cases of CS per 100 000 live births in 80% of countries",
          "95% reduction in incidence of chronic HBV infections"
        ],
        [
          "EMTCT impact targets",
          "A population case rate of new paediatric HIV infections due to MTCT of ≤50 cases per 100 000 live births\nMTCT rate of HIV of <2% in non-breastfeeding populations OR <5% in breastfeeding populations",
          "A case rate of CS of ≤50 per 100 000 live births",
          "≤0.1% prevalence* HBsAg in children ≤5 years oldᵃ,ᵇ\nAdditional target ≤2% MTCT rate (for countries using targeted timely HepB-BD)"
        ],
        [
          "EMTCT process/programmatic targets",
          "ANC coverage (at least one visit (ANC-1)) of ≥95%\nCoverage of HIV testing of pregnant women of ≥95%\nART coverage of pregnant women living with HIV of ≥95%",
          "ANC coverage (at least one visit (ANC-1)) of ≥95%\nCoverage of syphilis testing of pregnant women of ≥95% among those who attended at least one ANC visit\nAdequate syphilis treatment (see Box 3.6) of syphilis-seropositive pregnant women of ≥95%",
          "Countries with universal timely HepB-BD\n≥90% HepB3 vaccine coverage\n≥90% HepB-BD coverageᶜ\nCountries with targeted timely HepB-BD or without universal timely HepB-BD\n≥90% HepB3 vaccine coverage\n≥90% HepB-BD coverage\n≥90% coverage of maternal HBsAg testing\n≥90% coverage with antivirals for eligible HBsAg-positive pregnant womenᵈ"
        ]
      ],
      "notes": "HBV=hepatitis B virus; GHSS=global health sector strategy; CS=congenital syphilis; EMTCT=elimination of mother-to-child transmission; MTCT=mother-to-child transmission; ANC=antenatal care; ART=antiretroviral therapy; HepB3=three doses of hepatitis B vaccine (infant vaccination); HepB-BD=hepatitis B birth dose vaccine; HBsAg=hepatitis B surface antigen; UNGA=United Nations General Assembly\na Childhood prevalence is a proxy for HBV incidence.\nb The ≤0.1% HBsAg prevalence can be measured among either 5 year olds, 1 year olds or those aged 1–5 years, according to existing country surveillance and data collection activities. For those regions and countries with a long history of high hepatitis B vaccination coverage (e.g. WHO Region of the Americas), and that already conduct school-based serosurveys, there could be flexibility to conduct serosurveys in older children >5 years.\nc Timely birth dose (HepB-BD) is defined as within 24 hours of birth.\nd In accordance with national policies or WHO 2020 guidelines on use of antiviral prophylaxis on PMTCT of HBV",
      "narratives": {
        "en": "The table summarizes, for the elimination of mother-to-child transmission (EMTCT) of HIV, syphilis and hepatitis B virus (columns), the 2030 aspirational targets, the EMTCT impact targets and the process/programmatic targets (rows).",
        "ar": "يلخّص الجدول، فيما يخص التخلص من انتقال فيروس العوز المناعي البشري والزهري وفيروس التهاب الكبد B من الأم إلى الطفل (الأعمدة)، الغايات الطموحة لعام 2030، وغايات الأثر، وغايات العمليات/البرامج (الصفوف).",
        "zh": "该表针对消除艾滋病毒、梅毒和乙型肝炎病毒母婴传播（列），概述了2030年愿景目标、消除母婴传播的影响目标以及过程/规划目标（行）。",
        "es": "La tabla resume, para la eliminación de la transmisión maternoinfantil (ETMI) del VIH, la sífilis y el virus de la hepatitis B (columnas), las metas aspiracionales para 2030, las metas de impacto de la ETMI y las metas de proceso/programáticas (filas).",
        "fr": "Le tableau résume, pour l’élimination de la transmission mère-enfant (ETME) du VIH, de la syphilis et du virus de l’hépatite B (colonnes), les cibles ambitieuses pour 2030, les cibles d’impact de l’ETME et les cibles de processus/programmatiques (lignes).",
        "ru": "В таблице для элиминации передачи ВИЧ, сифилиса и вируса гепатита B от матери ребенку (столбцы) кратко представлены перспективные целевые показатели на 2030 г., целевые показатели воздействия и целевые показатели процесса/программ (строки)."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 3.1",
      "caption": "Table 3.1. Country options for applications for single, dual or triple validation of EMTCT of HIV, syphilis and HBV",
      "pages": [
        28
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "HIV"
        },
        {
          "titles": "Syphilis"
        },
        {
          "titles": "HBV"
        }
      ],
      "rows": [
        [
          "Single validation",
          "●",
          "",
          ""
        ],
        [
          "",
          "",
          "●",
          ""
        ],
        [
          "",
          "",
          "",
          "●*"
        ],
        [
          "Dual validation",
          "●",
          "●",
          ""
        ],
        [
          "",
          "●",
          "",
          "●"
        ],
        [
          "",
          "",
          "●",
          "●"
        ],
        [
          "Triple validation",
          "●",
          "●",
          "●"
        ]
      ],
      "notes": "● = option available (the HBV single-validation dot is printed in a different colour).\n*Single validation for HBV is done at the regional level (3). Upon special request from the regional validation secretariat or committee, single validation for HBV may be reviewed at the global level and will include reporting on HIV and syphilis.",
      "narratives": {
        "en": "The table shows, with dots, the combinations of infections (HIV, syphilis, HBV) for which a country may apply for single, dual or triple validation of EMTCT.",
        "ar": "يبيّن الجدول، باستخدام نقاط، توليفات العداوى (فيروس العوز المناعي البشري، والزهري، وفيروس التهاب الكبد B) التي يجوز للبلد أن يطلب بشأنها التحقق الأحادي أو الثنائي أو الثلاثي من التخلص من انتقالها من الأم إلى الطفل.",
        "zh": "该表用圆点标示国家可申请单一、双重或三重消除母婴传播认证的感染组合（艾滋病毒、梅毒、乙型肝炎病毒）。",
        "es": "La tabla indica, con puntos, las combinaciones de infecciones (VIH, sífilis, VHB) para las que un país puede solicitar la validación simple, doble o triple de la ETMI.",
        "fr": "Le tableau indique, par des points, les combinaisons d’infections (VIH, syphilis, VHB) pour lesquelles un pays peut demander une validation simple, double ou triple de l’ETME.",
        "ru": "В таблице точками отмечены сочетания инфекций (ВИЧ, сифилис, ВГВ), по которым страна может подать заявку на одинарную, двойную или тройную валидацию элиминации передачи от матери ребенку."
      },
      "csv": "tables/table-3-1.csv"
    },
    {
      "label": "Table 4.1",
      "caption": "Table 4.1. Key steps for human rights, gender equality and community engagement in the validation assessment",
      "pages": [
        53
      ],
      "columns": [
        {
          "titles": "Phase"
        },
        {
          "titles": "Roles and responsibilities"
        },
        {
          "titles": "Responsible entity"
        }
      ],
      "rows": [
        [
          "1",
          "Ensure that validation structures include representatives of networks of women living with HIV and HBV.",
          "National validation structures"
        ],
        [
          "",
          "Review and understand the human rights, community engagement and gender equality criteria and tool.",
          ""
        ],
        [
          "",
          "Select an independent focal point/consultant with human rights, community engagement and gender expertise to support the process.",
          ""
        ],
        [
          "",
          "Identify and engage with networks of women living with HIV or HBV and other relevant community organizations and provide any technical/financial support needed for their engagement from the beginning of the validation process.",
          ""
        ],
        [
          "2",
          "Review and understand the human rights, community engagement and gender equality criteria, methodology and tool.",
          "Independent consultant or focal point"
        ],
        [
          "",
          "Conduct a literature/desk review to respond to questions in all sections.",
          ""
        ],
        [
          "",
          "Develop and implement a plan to consult/interview relevant stakeholders, including government officials and officers, service providers, civil society organizations, human rights and gender experts and communities of women.",
          ""
        ],
        [
          "",
          "Coordinate with networks of women living with HIV, HBV and other women’s organizations to support them in organizing and facilitating an independent consultation with women who use services in order to prepare independent feedback for the tool.",
          ""
        ],
        [
          "",
          "Triangulate and analyse data to draft a report that includes the different perspectives as part of the assessment.",
          ""
        ],
        [
          "3",
          "Organize a multi-stakeholder forum to review key findings of the assessment.",
          "National validation structures"
        ],
        [
          "",
          "Support facilitation of a dialogue to review findings and build consensus on gaps and possible solutions in readiness for validation.",
          ""
        ],
        [
          "",
          "Follow up on recommended actions from the multistakeholder forum.",
          ""
        ],
        [
          "",
          "Provide feedback to all stakeholders consulted, including networks and organizations of women",
          ""
        ]
      ],
      "narratives": {
        "en": "The table sets out the key steps for integrating human rights, gender equality and community engagement into the validation assessment, grouped in three phases, with the roles and responsibilities in each phase and the responsible entity (national validation structures or an independent consultant or focal point).",
        "ar": "يعرض الجدول الخطوات الرئيسية لإدماج حقوق الإنسان والمساواة بين الجنسين والمشاركة المجتمعية في تقييم التحقق، مقسّمة إلى ثلاث مراحل، مع الأدوار والمسؤوليات في كل مرحلة والجهة المسؤولة (هياكل التحقق الوطنية أو استشاري مستقل أو جهة اتصال).",
        "zh": "该表列出将人权、性别平等和社区参与纳入认证评估的关键步骤，分为三个阶段，并列明每个阶段的角色和职责以及负责实体（国家认证机构或独立顾问/联络人）。",
        "es": "La tabla presenta los pasos clave para integrar los derechos humanos, la igualdad de género y la participación comunitaria en la evaluación de la validación, agrupados en tres fases, con las funciones y responsabilidades de cada fase y la entidad responsable (estructuras nacionales de validación o un consultor o coordinador independiente).",
        "fr": "Le tableau présente les étapes clés pour intégrer les droits humains, l’égalité des genres et l’engagement communautaire dans l’évaluation de la validation, regroupées en trois phases, avec les rôles et responsabilités de chaque phase et l’entité responsable (structures nationales de validation ou consultant ou point focal indépendant).",
        "ru": "В таблице изложены ключевые шаги по учету прав человека, гендерного равенства и участия сообществ в оценке для валидации, сгруппированные в три этапа, с указанием функций и обязанностей на каждом этапе и ответственной структуры (национальные структуры по валидации или независимый консультант/координатор)."
      },
      "csv": "tables/table-4-1.csv"
    },
    {
      "label": "Table 5.1",
      "caption": "Table 5.1. Prevalence requirements, indicators and targets for certification on the PTE of MTCT of HIV, syphilis, and/or HBV",
      "pages": [
        55,
        56
      ],
      "columns": [
        {
          "titles": "Tier"
        },
        {
          "titles": "Infection"
        },
        {
          "titles": "Impact indicators for at least one year"
        },
        {
          "titles": "Process/programme indicators for at least two years"
        }
      ],
      "rows": [
        [
          "Bronze tier",
          "HIV",
          "MTCT of HIV rate of <2% in non-breastfeeding populations OR <5% in breastfeeding populations\nA case rate of new paediatric HIV infections due to MTCT of ≤750 cases per 100 000 live births",
          "≥90% ANC coverage (at least one visit) (ANC-1)\n≥90% HIV testing coverage in pregnant women\n≥90% ART coverage in pregnant women living with HIV"
        ],
        [
          "",
          "Syphilis",
          "A case rate of CS of ≤750 per 100 000 live births",
          "≥90% ANC coverage (at least one visit) (ANC-1)\n≥90% syphilis testing coverage in pregnant women attending ANC\n≥90% treatment coverage in syphilis-seropositive pregnant women"
        ],
        [
          "",
          "HBVᵇ",
          "Not required",
          "≥90% coverage of HepB3 infant vaccination\nImplementation of universal timely HepB-BD policy"
        ],
        [
          "Silver tier",
          "HIV",
          "MTCT of HIV rate of <2% in non-breastfeeding populations OR <5% in breastfeeding populations\nA case rate of new paediatric HIV infections due to MTCT of ≤500 cases per 100 000 live births",
          "≥90% ANC coverage (at least one visit) (ANC-1)\n≥90% HIV testing coverage in pregnant women\n≥90% ART coverage in pregnant women living with HIV"
        ],
        [
          "",
          "Syphilis",
          "A case rate of CS of ≤500 per 100 000 live births",
          "≥90% ANC coverage (at least one visit) (ANC-1)\n≥90% syphilis testing coverage in pregnant women attending ANC\n≥90% treatment coverage of syphilis-seropositive pregnant women"
        ],
        [
          "",
          "HBVᵇ",
          "Not required",
          "≥90% coverage of HepB3 infant vaccination\n≥50% coverage of universal timely HepB-BD\nAvailability of antenatal HBsAg testing in the public sector"
        ],
        [
          "Gold tier",
          "HIV",
          "MTCT of HIV rate of <2% in non-breastfeeding populations OR <5% in breastfeeding populations\nA case rate of new paediatric HIV infections due to MTCT of ≤250 cases per 100 000 live births",
          "≥95% ANC coverage (at least one visit) (ANC-1)\n≥95% HIV testing coverage in pregnant women\n≥95% ART coverage in pregnant women living with HIV"
        ],
        [
          "",
          "Syphilis",
          "A case rate of CS of ≤250 per 100 000 live births",
          "≥95% ANC coverage (at least one visit) (ANC-1)\n≥95% HIV testing coverage in pregnant women attending ANC\n≥95% treatment coverage for syphilis-seropositive pregnant women"
        ],
        [
          "",
          "HBVᵇ",
          "Not required",
          "≥90% coverage of HepB3 infant vaccination\n≥90% coverage of universal timely HepB-BD\n>30% coverage of antenatal HBsAg testing"
        ]
      ],
      "notes": "Table continued on next page.\nCountries are required to achieve high coverage at the district level, as follows: ≥90% coverage in all districts for HepB3 in all tiers and ≥80% coverage in all districts for HepB-BD in gold tier and ≥50% for targeted timely HepB-BD in all districts for the silver tier.\n(The superscript b on “HBV” has no matching footnote on these pages.)",
      "narratives": {
        "en": "For each tier of the path to elimination (bronze, silver, gold) and each infection (HIV, syphilis, HBV), the table lists the impact indicators to be met for at least one year and the process/programme indicators to be met for at least two years.",
        "ar": "يسرد الجدول، لكل مستوى من مستويات المسار نحو التخلص (البرونزي، والفضي، والذهبي) ولكل عدوى (فيروس العوز المناعي البشري، والزهري، وفيروس التهاب الكبد B)، مؤشرات الأثر الواجب تحقيقها لمدة سنة واحدة على الأقل ومؤشرات العمليات/البرامج الواجب تحقيقها لمدة سنتين على الأقل.",
        "zh": "该表针对消除路径的每一级（铜级、银级、金级）和每种感染（艾滋病毒、梅毒、乙型肝炎病毒），列出须至少保持一年的影响指标和须至少保持两年的过程/规划指标。",
        "es": "Para cada nivel del camino hacia la eliminación (bronce, plata, oro) y cada infección (VIH, sífilis, VHB), la tabla enumera los indicadores de impacto que deben cumplirse durante al menos un año y los indicadores de proceso/programa que deben cumplirse durante al menos dos años.",
        "fr": "Pour chaque niveau du chemin vers l’élimination (bronze, argent, or) et chaque infection (VIH, syphilis, VHB), le tableau énumère les indicateurs d’impact à atteindre pendant au moins un an et les indicateurs de processus/programme à atteindre pendant au moins deux ans.",
        "ru": "Для каждого уровня на пути к элиминации (бронзовый, серебряный, золотой) и каждой инфекции (ВИЧ, сифилис, ВГВ) в таблице перечислены показатели воздействия, которые должны достигаться не менее одного года, и показатели процесса/программ, которые должны достигаться не менее двух лет."
      },
      "csv": "tables/table-5-1.csv"
    },
    {
      "label": "Table 5.2",
      "caption": "Table 5.2. Scenarios of prevalence, indicators and targets for certification on the PTE of MTCT of HIV",
      "pages": [
        57
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "HIV prevalence in ANC"
        },
        {
          "titles": "HIV MTCT rate"
        },
        {
          "titles": "Expected HIV infant case rate/100 000"
        },
        {
          "titles": "Applicable tier"
        }
      ],
      "rows": [
        [
          "Certification of PTE: for countries with strong programmes but high ANC prevalence, which makes it virtually impossible to achieve the case rate criterion for validation",
          "5.0%",
          "<5.0",
          "<250",
          "Gold"
        ],
        [
          "",
          "7.0%",
          "<5.0",
          "<350",
          "Silver"
        ],
        [
          "",
          "9.0%",
          "<5.0",
          "<450",
          "Silver"
        ],
        [
          "",
          "11.0%",
          "<5.0",
          "<550",
          "Bronze"
        ],
        [
          "",
          "15.0%",
          "<5.0",
          "<750",
          "Bronze"
        ],
        [
          "Validation of EMTCT: for countries with indicator thresholds consistent with other public health control programmes and low enough to affirm elimination of new paediatric infections resulting from MTCT as a “public health problem”",
          "1.0%",
          "<5.0",
          "50",
          "Not applicable"
        ],
        [
          "",
          "2.0%",
          "2.5",
          "50",
          ""
        ],
        [
          "",
          "5.0%",
          "1.0",
          "50",
          ""
        ]
      ],
      "narratives": {
        "en": "The table gives scenarios combining HIV prevalence in antenatal care and the HIV MTCT rate, with the expected HIV infant case rate per 100 000 and the applicable tier, separately for certification on the path to elimination and for validation of EMTCT.",
        "ar": "يقدّم الجدول سيناريوهات تجمع بين معدل انتشار فيروس العوز المناعي البشري في رعاية ما قبل الولادة ومعدل انتقاله من الأم إلى الطفل، مع معدل حالات العدوى المتوقع بين الرضّع لكل 100000 والمستوى المنطبق، وذلك بشكل منفصل للإشهاد على المسار نحو التخلص وللتحقق من التخلص من الانتقال من الأم إلى الطفل.",
        "zh": "该表给出了将产前保健中的艾滋病毒流行率与艾滋病毒母婴传播率相结合的情景，以及每10万人中的预期婴儿艾滋病毒病例率和适用等级，分别针对消除路径认证和消除母婴传播认证。",
        "es": "La tabla presenta escenarios que combinan la prevalencia del VIH en la atención prenatal y la tasa de transmisión maternoinfantil del VIH, con la tasa prevista de casos de VIH en lactantes por 100 000 y el nivel aplicable, por separado para la certificación en el camino hacia la eliminación y para la validación de la ETMI.",
        "fr": "Le tableau présente des scénarios combinant la prévalence du VIH dans les soins prénatals et le taux de TME du VIH, avec le taux attendu de cas de VIH chez le nourrisson pour 100 000 et le niveau applicable, séparément pour la certification sur le chemin vers l’élimination et pour la validation de l’ETME.",
        "ru": "В таблице приведены сценарии, сочетающие распространенность ВИЧ среди посещающих женские консультации и коэффициент передачи ВИЧ от матери ребенку, с ожидаемым показателем случаев ВИЧ среди младенцев на 100 000 и соответствующим уровнем, отдельно для сертификации на пути к элиминации и для валидации элиминации."
      },
      "csv": "tables/table-5-2.csv"
    },
    {
      "label": "Table 6.1",
      "caption": "Table 6.1. Scenarios for HIV MTCT rate and infant case rate of HIV and CS in countries with small populations of pregnant women",
      "pages": [
        62
      ],
      "columns": [
        {
          "titles": "Number of pregnant women with HIV in one year",
          "group": "HIV MTCT rate for small countries"
        },
        {
          "titles": "Number of infant cases in one year",
          "group": "HIV MTCT rate for small countries"
        },
        {
          "titles": "Annual MTCT rate (%)",
          "group": "HIV MTCT rate for small countries"
        },
        {
          "titles": "4-year pooled MTCT rate (%)*",
          "group": "HIV MTCT rate for small countries"
        },
        {
          "titles": "Number of pregnant women in one year",
          "group": "Population case rate of new infant and young child HIV infections due to MTCT, or infant and young child case rate for syphilis for small countries"
        },
        {
          "titles": "Number of infant cases (HIV or syphilis) in one year",
          "group": "Population case rate of new infant and young child HIV infections due to MTCT, or infant and young child case rate for syphilis for small countries"
        },
        {
          "titles": "1-year infant case rate/100 000 LB",
          "group": "Population case rate of new infant and young child HIV infections due to MTCT, or infant and young child case rate for syphilis for small countries"
        },
        {
          "titles": "4-year pooled infant case rate*",
          "group": "Population case rate of new infant and young child HIV infections due to MTCT, or infant and young child case rate for syphilis for small countries"
        }
      ],
      "rows": [
        [
          "10",
          "1",
          "10%",
          "2.5",
          "500",
          "1",
          "200",
          "50"
        ],
        [
          "10",
          "2",
          "20%",
          "5",
          "600",
          "1",
          "167",
          "42"
        ],
        [
          "20",
          "1",
          "5%",
          "1.3",
          "700",
          "1",
          "143",
          "36"
        ],
        [
          "20",
          "2",
          "10%",
          "2.5",
          "1000",
          "2",
          "200",
          "50"
        ],
        [
          "30",
          "1",
          "3%",
          "0.8",
          "1500",
          "2",
          "133",
          "33"
        ],
        [
          "30",
          "2",
          "7%",
          "1.7",
          "2000",
          "2",
          "100",
          "25"
        ],
        [
          "40",
          "2",
          "5%",
          "1.3",
          "2500",
          "3",
          "120",
          "30"
        ],
        [
          "40",
          "3",
          "8%",
          "1.9",
          "3000",
          "3",
          "100",
          "25"
        ],
        [
          "50",
          "2",
          "4%",
          "1.0",
          "3500",
          "3",
          "86",
          "21"
        ],
        [
          "50",
          "3",
          "6%",
          "1.5",
          "4000",
          "4",
          "100",
          "25"
        ]
      ],
      "notes": "LB=live births; MTCT=mother-to-child transmission\n*Pooled MTCT rate calculations and pooled infant case rate calculations assume no additional infant cases are identified other than those presented for the 1-year period. These 4-year pooled estimates are calculated by multiplying the value in the first column (for example, number of pregnant women with HIV/year or number of live births/year) of each table by four and recalculating the MTCT rate and infant case rate.",
      "narratives": {
        "en": "The table gives worked scenarios for countries with small numbers of pregnant women: the left half shows annual and 4-year pooled HIV MTCT rates for given numbers of pregnant women with HIV and infant cases, and the right half shows 1-year and 4-year pooled infant case rates per 100 000 live births for HIV or syphilis.",
        "ar": "يقدّم الجدول سيناريوهات محسوبة للبلدان التي يقل فيها عدد الحوامل: يبيّن النصف الأيسر المعدلات السنوية والمجمّعة على 4 سنوات لانتقال فيروس العوز المناعي البشري من الأم إلى الطفل بحسب أعداد معينة من الحوامل المصابات بالفيروس وحالات الرضّع، ويبيّن النصف الأيمن معدلات حالات الرضّع لسنة واحدة والمجمّعة على 4 سنوات لكل 100000 ولادة حية لفيروس العوز المناعي البشري أو الزهري.",
        "zh": "该表为孕妇人数较少的国家提供计算情景：左半部分显示在给定感染艾滋病毒孕妇人数和婴儿病例数下的年度及4年合并艾滋病毒母婴传播率，右半部分显示艾滋病毒或梅毒每10万活产的1年及4年合并婴儿病例率。",
        "es": "La tabla presenta escenarios calculados para países con un número reducido de embarazadas: la mitad izquierda muestra las tasas anuales y agrupadas de 4 años de transmisión maternoinfantil del VIH para un número dado de embarazadas con VIH y de casos en lactantes, y la mitad derecha muestra las tasas de casos en lactantes de 1 año y agrupadas de 4 años por 100 000 nacidos vivos para el VIH o la sífilis.",
        "fr": "Le tableau présente des scénarios chiffrés pour les pays comptant peu de femmes enceintes : la moitié gauche indique les taux annuels et cumulés sur 4 ans de TME du VIH pour des nombres donnés de femmes enceintes vivant avec le VIH et de cas chez le nourrisson, et la moitié droite les taux de cas chez le nourrisson sur 1 an et cumulés sur 4 ans pour 100 000 naissances vivantes pour le VIH ou la syphilis.",
        "ru": "В таблице приведены расчетные сценарии для стран с небольшим числом беременных женщин: в левой половине показаны годовые и объединенные за 4 года коэффициенты передачи ВИЧ от матери ребенку при заданном числе беременных с ВИЧ и случаев у младенцев, в правой — однолетние и объединенные за 4 года показатели случаев у младенцев на 100 000 живорождений для ВИЧ или сифилиса."
      },
      "csv": "tables/table-6-1.csv"
    },
    {
      "label": "Table 8.1",
      "caption": "Table 8.1. Time intervals for assessing maintenance of validation",
      "pages": [
        68
      ],
      "columns": [
        {
          "titles": "Type of country"
        },
        {
          "titles": "Validation request"
        },
        {
          "titles": "Maintenance review time interval"
        }
      ],
      "rows": [
        [
          "Standard (HIV/syphilis)",
          "Single or dual",
          "3 years"
        ],
        [
          "Standard (HBV)",
          "Single",
          "5 years"
        ],
        [
          "Country applying for triple elimination (HIV/syphilis/HBV)",
          "Triple",
          "3 years (HIV/syphilis)\n6 years (HBV – reviewed at every other maintenance review)"
        ],
        [
          "Small population, low burden country (HIV/syphilis)",
          "Single or dual",
          "4 years"
        ],
        [
          "Small population, low burden country (HIV/syphilis/HBV)",
          "Triple",
          "5 years"
        ]
      ],
      "notes": "See Chapter 3 for options for combining validation requests",
      "narratives": {
        "en": "The table gives the time interval between maintenance-of-validation reviews for each type of country and validation request (single, dual or triple).",
        "ar": "يبيّن الجدول الفاصل الزمني بين استعراضات الحفاظ على التحقق لكل نوع من البلدان ونوع طلب التحقق (أحادي أو ثنائي أو ثلاثي).",
        "zh": "该表列出每类国家和每种认证申请（单一、双重或三重）的维持认证审查时间间隔。",
        "es": "La tabla indica el intervalo de tiempo entre las revisiones de mantenimiento de la validación para cada tipo de país y de solicitud de validación (simple, doble o triple).",
        "fr": "Le tableau indique l’intervalle entre les examens du maintien de la validation pour chaque type de pays et de demande de validation (simple, double ou triple).",
        "ru": "В таблице указаны интервалы между обзорами сохранения статуса валидации для каждого типа страны и вида заявки на валидацию (одинарная, двойная или тройная)."
      },
      "csv": "tables/table-8-1.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "not-extracted",
      "note": "split one section per page; no contents was trusted"
    },
    {
      "kind": "sections",
      "state": "partial",
      "count": 86,
      "note": "one per page, not by heading"
    },
    {
      "kind": "figures",
      "state": "partial",
      "count": 2,
      "note": "3 captioned in the text"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 7
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p5); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p5); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 86,
      "note": "86 of 86 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-349550"
  }
}
